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ABSTRACT 
Background 
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Patients diagnosed 
with metastatic RCC (mRCC) have shorter overall survival compared to those diagnosed at earlier 
stages. Several targeted therapies, which cost from $7,000 - $16,000 per month have been 
approved since 2005 to treat mRCC. In addition, there is a growing interest in the use of 
cytoreductive nephrectomy (CN) with targeted therapies among mRCC patients. However, little 
is known regarding the economic burden of RCC and role of CN and prescribing patterns of 
targeted therapies among older mRCC patients. 
Objectives  
1) To assess the economic burden of RCC among older adults in the targeted therapy era 
2) To compare the overall survival (OS) and total healthcare cost (THC) among older mRCC 
patients receiving CN and targeted therapy versus patients receiving targeted therapy alone 3) To 
describe prescribing patterns of targeted therapies and associated OS and THC among older mRCC 
patients. 
Methods 
This dissertation was conducted using the Surveillance Epidemiology and End Results 
(SEER) - Medicare linked data. For the first objective, the study included a prevalent cohort of 
RCC patients from 2013, diagnosed during 2005 - 2013 and continuously enrolled in Medicare. 
RCC patients were matched to non-cancer beneficiaries using propensity score matching. 
Generalized linear models estimated the incremental healthcare costs. Incremental total healthcare 
cost (THC) was multiplied by the estimated number of RCC patients on Medicare to calculate the 
total economic burden of RCC. For the second objective, we included patients diagnosed with 
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mRCC between 2007-2014 and compared overall survival (OS), and THC between patients who 
received CN + targeted therapy and targeted therapy alone. A propensity score based inverse 
probability of treatment weighting (IPTW) method was used to balance the two treatment groups. 
A Cox proportional hazard model assessed the risk for death and a GLM compared healthcare 
costs between the groups. For the third objective, patients with mRCC were defined as patients 
who were diagnosed at stage-IV or at earlier stages but were currently using targeted therapies. 
Further, we restricted our sample to patients who initiated targeted therapy. We described the 
frequencies of the most common first and second line targeted therapies. We also described OS 
and THC per month for clear-cell and non-clear cell mRCC for each therapy and line of therapy. 
Results 
The first study included 10,392 each of RCC and control patients. The average THC 
associated with RCC was $7,419. The average THC was $4,584 for patients diagnosed at stage-I, 
$4,727 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. The annual economic burden 
of RCC on Medicare was estimated to be $1.5 billion. The second study included 471 mRCC 
patients that received CN + targeted therapy or targeted therapy alone. The median OS from the 
adjusted survival curves was significantly higher (p <0.0001) for CN + targeted therapy group (15 
months) than the targeted therapy alone group (10 months). CN + targeted therapy group had 0.63 
times the risk of death (HR = 0.63) compared to the targeted therapy alone group. The adjusted 
total healthcare cost per month was $17,159 for CN + targeted therapy group and $18,120 for the 
targeted therapy alone group (p = 0.4389). The third study included 915 mRCC patients with 
targeted therapy prescription. Among clear cell mRCC patients, sunitinib (384, 48%) and 
everolimus (101, 13%) were the top first and second line targeted therapies. Of 109 non-clear cell 
patients, sunitinib (n = 35, 32%) and temsirolimus (n = 26, 24%) were the most commonly 
xiii 
 
prescribed first line targeted therapies. Among patients who received multiple lines, VEGF-mTOR 
was the most commonly prescribed sequence. The median OS and median monthly THC was 
similar across targeted therapy sequences. 
Conclusions 
The economic burden of RCC varied substantially between early stage and metastatic 
patients. Among mRCC patients, use of CN among targeted therapy users was associated with a 
higher median OS and similar monthly THC over a lifetime. Sunitinib and everolimus were the 
most common first and second line targeted therapies among mRCC patients. The descriptive 
analysis suggested that OS and THC were similar across types of targeted therapy sequences. 
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Chapter 1: Introduction 
Renal Cell Carcinoma 
Epidemiology  
Renal cell carcinoma (RCC) is the most common type of kidney cancer. About 9 out of 10 
kidney cancers are RCC. 1, 2 Other forms of kidney cancer include transitional cell carcinomas, 
Wilms tumors, and renal sarcomas. RCC usually grows as a single tumor within a kidney, however, 
sometimes multiple tumors can be found in one or both the kidneys. A very early stage RCC is 
often asymptomatic but large tumors often show symptoms that include presence of blood in the 
urine, lower back pain on one side, mass on the side or lower back, fatigue, loss of weight, fever, 
and anemia. Subtypes of RCC include clear-cell RCC, which accounts for 70% of cases, Papillary 
(10%), Chromophobe (5%) and rare types (5%) and unclassified (10%). These subtypes play an 
important role in deciding treatment or in finding out if cancer might be due to inherited genetic 
syndrome.1, 2  
The American Cancer Society (ACS) estimated that in the U.S, in 2017, approximately 
63,700 new kidney cancer cases (39,650 in men and 23,050 in women) would be diagnosed and 
14,240 people (9,240 men and 5,000 women) would die from this disease.1 These numbers include 
all types of kidney and renal pelvis cancers. Overall, the lifetime risk for developing kidney cancer 
is about 1 in 63 (1.6%). Incidence for RCC has increased from 9 per 100,000 persons in 1990s to 
15 in 2007 and leveled off in the last few years.1, 2 The median age of RCC diagnosis is 64 years 
and it very uncommon among individuals aged < 45 years. Men often have a higher risk (~2 times) 
for RCC than women. Other risk factors for RCC include smoking, obesity, high blood pressure, 
African American and American Indian race, workplace exposure to substances such as cadmium, 
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family history, certain medicines such as diuretics, an advanced kidney disease that requires 
dialysis and presence of genetic conditions such as Von Hippel-Lindau (VHL) disease.1 
Staging and Survival  
Cancer staging indicates the extent of the disease and its prognosis. The most common 
staging system for RCC is that of the American Joint Committee on Cancer (AJCC).1, 3 Stage-I 
indicates that the tumor is 7 cm across or smaller, located only in the kidney and has not spread to 
lymph nodes or distant organs. Stage-II indicates that the tumor is larger than 7 cm across but is 
still only in the kidney. There is no spread to lymph nodes or distant organs. Stage-III indicates 
that the tumor has spread to the major blood vessels – the renal vein and inferior vena cava, into 
the tissue surrounding the kidney, or to nearby lymph nodes. Stage-IV indicates that the tumor has 
spread outside of the kidney to the adrenal gland, to distant lymph nodes, or to other organs.  
According to statistics presented by the Surveillance, Epidemiology and End Result 
(SEER) program, about 65% of RCC cases are diagnosed at localized stage, 16% have 
involvement of regional lymph nodes, 16% are diagnosed with distant metastasis and 3% have 
unknown stage.2 Further, literature suggests that about 15%-40% of patients are diagnosed at the 
metastatic stage and among those diagnosed at early stages; over 30-33% eventually progress to 
metastatic stage.4, 5 The five-year survival rate for RCC patients based on data from 2007 to 2013 
was 74.1%; however, it varied by cancer stage. Survival rates were 93% for localized, 63% for 
regional, 38% for unknown and 12% for metastatic renal cell carcinoma (mRCC) patients.2  
Treatment for Stages I-III 1  
Patients with localized tumor are often treated with surgery that includes partial or radical 
(complete) nephrectomy. Partial nephrectomy removes portions of a kidney while radical 
nephrectomy involves complete removal of kidney. Partial nephrectomy is often the treatment of 
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choice in tumors up to 7 cm in size. Surgery may involve removal of lymph nodes near the kidney, 
especially if they are enlarged. If cancer has grown into the nearby vein (stage-III), surgery is 
needed to remove a tumor from the veins. Adjuvant therapy, which, includes surgery followed by 
treatment with targeted therapy, chemotherapy, or radiation therapy has also been tried as another 
option among Stage-III patients. So far, it has not been shown to help patients live longer. 1 There 
are, however, ongoing clinical trials that are looking at adjuvant treatment for locally advanced 
RCC. Patients that cannot undergo surgery because of other serious medical problems, patients 
may be given local treatments such as cryotherapy, radiofrequency ablation, or arterial 
embolization or radiation therapy. These options, however, are often considered as less effective 
options than surgery. Active surveillance is another option for some people with small kidney 
tumors. In this approach, the tumor is watched closely (with CTs or ultrasounds) and only treated 
if it grows.1   
Treatment for Stage IV / mRCC  
 Treatment among mRCC patients depends largely on the extent of tumor growth and 
overall health status; however, for the most part, it involves the use of systemic therapy with 
immunotherapy or targeted therapy agents.1 Before 2005, the treatment of mRCC mainly included 
cytokines: high dose interleukin-2 and interferon-alpha. However, both drugs were associated with 
low response rate, higher toxicity and improvement of fewer than 6-12 months in the OS.6, 7 From 
2005 to 2012, the US Food and Drug Administration (FDA) approved seven targeted therapies to 
treat mRCC.8-12 These therapies included vascular endothelial growth factor (VEGF) receptor 
tyrosine kinase inhibitors (TKI) sorafenib, sunitinib, pazopanib, and axitinib; the mammalian 
target of rapamycin inhibitors (mTOR) everolimus and temsirolimus; and the anti-VEGF 
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monoclonal antibody bevacizumab. Everolimus and axitinib are approved only as second-line 
treatments. From 2016, cabozantinib, lenvatinib, and nivolumab were approved for mRCC. 
Details of these therapies are given in Table 1.  
 
Table 1. FDA approved targeted therapies for metastatic Renal Cell Carcinoma  
 
Drug FDA 
approval 
Mechanism Line of therapy Dosage Regimen 
Sorafenib 2005 VEGF- TKI First & Second 400 mg twice a day 
Sunitinib 2006 VEGF- TKI First & Second 50 mg once a day, 4 weeks 
on 2 weeks off 
Temsirolimus 2007 mTOR First & Second 25 mg IV infusion once 
weekly. 
Everolimus 2009 mTOR Second only 10 mg once daily. 
bevacizumab + 
interferon-alfa 
2009 Anti-VEGF First & Second 10 mg/kg IV every 2 weeks 
+ interferon alfa 
Pazopanib 2009 VEGF-TKI First & Second 800 mg / day 
Axitinib 2011 VEGF-TKI Second only 5-10 mg twice a day 
Cabozantinib  2016 TKI with 
multiple 
pathway 
inhibitor 
First & Second 60 mg per day 
Lenvatinib 2016 VEGF-TKI Second 18 mg per day with 
everolimus 
Nivolumab  2016 PD -1 First and second 240 mg every 2 weeks 
 
Sequencing of Targeted Therapies 
 Patients treated with first-line targeted therapy often develop resistance in 6-11 months and 
as a result, need subsequent lines of therapy to control disease progression.9, 13 Several studies have 
assessed the appropriate sequence of targeted therapies to improve OS. Based on previous studies, 
the most common sequences in clinical practice included VEGF followed by mTOR and VEGF 
followed by VEGF.14-16 Some patients with poor risk may receive mTOR as a first line followed 
by VEGF. Studies which compared OS between VEGF-VEGF and VEGF-mTOR found no 
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significant difference in the OS between the sequences.17, 18 The National Comprehensive Cancer 
Network (NCCN) develops evidence-based guidelines to help healthcare professionals in 
oncology to decide appropriate treatment strategy for cancer patients. Category-1 
recommendations indicate uniform consensus about the appropriateness of intervention among 
NCCN panel members based on a high-level of evidence; category-2A indicates uniform 
consensus based on a lower level of evidence; category-2B indicates some consensus based on a 
lower level of evidence and category-3 indicates major disagreement about the appropriateness of 
the intervention.19 The NCCN guidelines during 2007-2012 included sunitinib, pazopanib, and 
bevacizumab/interferon with category-1 recommendation and sorafenib with category-2A 
recommendation for the first-line treatment. Recommendations for the second line therapy 
included all of the above agents and everolimus. However, axitinib and everolimus have a 
category-1 recommendation as second-line treatments 19-21 No recommendations were made for 
the use of third-line use of targeted therapies. 
 
Role of Cytoreductive Nephrectomy (CN)  
  Prior to the targeted therapy era, CN was considered as a preferred treatment option among 
mRCC patients that were eligible for surgery. Two RCTs demonstrated that the use of CN in 
addition to cytokine therapies resulted in improved OS by additional 6 months.22, 23 As a result, 
CN followed by interferon-alpha had level-1 evidence to treat mRCC patients. However, with the 
approval of targeted therapies which were more effective than cytokine therapies, the role of CN 
has been questioned. Some studies have found the use of CN decreased after 2005.24, 25 However, 
a few retrospective studies conducted in the targeted therapy era suggested that CN may still play 
an important role in improving OS among mRCC patients who received targeted therapies.26, 27 
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Two prospective trials are also ongoing to understand the efficacy of CN among targeted therapy 
users.28 However, their results may be limited based on their selection criteria and thereby not 
generalizable to all patients diagnosed with mRCC. 
Economic Burden of RCC 
Diagnosis and treatment of RCC can impose a significant economic burden on the 
healthcare system, patients, and their caregivers. Economic burden typically includes direct 
medical and non-medical costs and indirect cost, which include the cost associated with 
absenteeism, mortality, and loss of employment. About 46% of all RCC patients are on Medicare 
making it the largest payer for RCC patients in the U.S.1, 29  
According to a review published in 2010, the economic burden of RCC in the U.S ranged 
from $600 million to $5.19 billion, with annual per-patient medical costs between $16,488 and 
$43,805 (2009 USD).30 In 2006, the economic burden specifically among mRCC patients was 
estimated to be between $107 to $556 million (2006 USD) in the US.31 In another study, the 
average annual direct medical cost among older RCC patients was $11,169; and varied from 
$24,694 in the initial, $6,218 in the continuous, to $26,784 in the late phase of the survival curve 
among RCC patients (2009 USD).32 Further, costs among patients treated with targeted therapies 
were 3-5 times higher than those for patients not treated with targeted therapy. Higher late phase 
cost and high cost among targeted therapy users suggest that the burden among patients with 
mRCC may increase as patients would receive more lines of therapies during to expanding 
landscape of systemic therapies. 
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Rationale  
 A number of studies assessed the economic burden of RCC in the cytokine era. However, 
only one study was conducted during the earlier years of the targeted therapy era.32 Further, costs 
among patients on Medicare Part D plans were not assessed as Part D data was not available until 
2007. As a result, little is known about the economic burden of RCC in the targeted therapy era. 
Further, economic burden by stage at which cancer is diagnosed is not well understood. Further, 
no study has projected the total economic burden to the entire Medicare population. As the 
landscape of targeted therapies continues to evolve, patients are more likely to receive multiple 
lines of targeted therapies than they received in the past.  This would increase healthcare cost to 
Medicare. On the other side, for early stage patients, use of active surveillance, advanced imaging, 
and minimally invasive surgical techniques may result in cost savings. As a result, it is important 
to understand the economic burden of RCC in the targeted therapy era.  
 Among mRCC patients, the role of CN was well established before targeted therapies were 
approved. However, few studies have assessed the effects of CN and targeted therapy on OS of 
mRCC patients in the targeted therapy era.26, 27 Further, none of the studies were specifically 
conducted among older adults. The socioeconomic and clinical predictors of CN and/or targeted 
therapy use among Medicare patients and the healthcare costs associated with the use of CN and 
targeted therapy are not well understood among Medicare patients. Examination of OS and 
healthcare cost would provide real-world evidence on the use of CN and targeted therapy among 
older adults.  
As the landscape of targeted therapies expanded from 2005 - 2012, a number of studies 
assessed sequencing of targeted therapies and its association with the OS. 14-16 However, none of 
the studies assessed prescribing patterns among older mRCC patients. Availability of several 
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targeted therapies, patients’ and physicians’ preferences, older age, frailty, drug interactions and 
comorbidities may complicate prescribing patterns of targeted therapies among older adults. 
Therefore, one of the aims of this dissertation is to describe prescribing patterns, OS and healthcare 
costs among mRCC patients on targeted therapies.  
Specific Aims 
This dissertation included three specific aims, which formed the basis for three research studies. 
These studies and research questions that they address are listed below.  
Study 1: Economic Burden of Renal Cell Carcinoma among Older Adults in the Targeted 
Therapy Era. 
Research Questions:  
1. What is the average direct healthcare cost associated with RCC in a given year? 
2. What is the total economic burden of RCC on Medicare? 
3. How do the average cost and the total economic burden vary by stage at diagnosis? 
4. What are the most common drivers of total healthcare cost? 
Study 2: Utilization of Targeted Therapy and Cytoreductive Nephrectomy among Older 
Adults with Metastatic Renal Cell Carcinoma: Analysis of Survival and Healthcare Costs 
Research Questions:  
1. What is the prevalence of targeted therapy and cytoreductive nephrectomy use among 
older mRCC patients? 
2. What are the sociodemographic and clinical predictors of mRCC patients receiving CN 
and /or targeted therapy? 
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3. Is there a difference in the overall survival between mRCC patients who received CN and 
targeted therapy versus targeted therapy alone? 
4. Is there a difference in the total healthcare cost between mRCC patients who received CN 
and targeted therapy versus targeted therapy alone? 
Study 3: Prescribing Patterns of Targeted Therapies, Overall Survival, and Total Healthcare 
Cost among Older Adults with Metastatic Renal Cell Carcinoma in the U.S 
Research Questions:  
1. What proportion of mRCC patients received two or more lines of targeted therapies? 
2. What were the most common targeted therapy sequences among mRCC patients? 
3. How did overall survival vary by the targeted therapy sequences? 
4. How did total healthcare costs vary by the targeted therapy sequences? 
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Chapter 2 
Study 1: Economic Burden of Renal Cell Carcinoma among Older Adults in the Targeted 
Therapy Era 
ABSTRACT 
Objective 
To assess the economic burden of renal cell carcinoma (RCC) among older adults on Medicare.  
Methods 
The study analyzed the Surveillance Epidemiology and End Result - Medicare linked data. We 
included a prevalent cohort of RCC patients from 2013, diagnosed during 2005 - 2013, and 
continuously enrolled in Medicare. RCC patients were matched to non-cancer beneficiaries using 
propensity score matching. Healthcare costs were calculated using a phase-based approach, which 
classified patients into early, continuing and late phases of care. Generalized linear models 
estimated average annual incremental costs. Incremental total healthcare cost (THC) was 
multiplied by the estimated number of RCC patients on Medicare to calculate the total economic 
burden of RCC. 
Results 
The study included 10,392 each of RCC and control patients. The average annual THC associated 
with RCC was $7,419 for all phases, $22,752 for initial phase, $4,860 for continuing phase and 
$13,232 for the late phase of care. The average THC was $4,584 for patients diagnosed at stage-I, 
$4,7272 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. For patients diagnosed at 
stages I-III, hospital cost (approximately $1,500 - $3,400) was the largest component of THC. For 
stage-IV patients, prescription drug cost ($11,747) was the largest component of THC. The annual 
economic burden of RCC on Medicare was estimated to be $1.51 billion. 
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Conclusions 
Economic burden of RCC varied substantially between early stage and metastatic patients. This 
research provided a baseline that can be used to assess the economic value of emerging therapies 
among older RCC patients. 
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BACKGROUND 
 
Renal cell carcinoma (RCC) is the most common type of kidney cancer. In 2017, 
approximately 63,990 new kidney cancer cases would be diagnosed and 14,440 people would die 
from this disease.1 The median age of RCC diagnosis is 64 years. Medicare covers about 46% of 
RCC patients.2, 3 As the number of older adults continues to increase, the burden of management 
of RCC on Medicare will be substantial.  
Management of RCC has evolved over time. Smaller tumors (≤ 4 cm) are now typically 
managed with active surveillance, cryotherapy, radiofrequency ablation or partial nephrectomy. 
Patients with localized but larger tumors (≥ 4 cm) are treated with nephrectomy.2, 4, 5 Significant 
changes in treatment patterns also occurred in the management of metastatic RCC (mRCC). Until 
2005, systemic therapy for mRCC included the use of interleukin-2 and interferon-alfa.6, 7 From 
2005, targeted therapies, which cost from $5,000 – $15,000 per month, were approved to treat 
mRCC. These included sorafenib, sunitinib, and temsirolimus, pazopanib, everolimus, 
bevacizumab, and axitinib.8-11 Recently, FDA approved cabozantinib in intermediate and poor risk 
patients as a first line therapy12 and programmed death (PD)-1 targeted check-point inhibitor, 
nivolumab as a 2nd line therapy.13 In addition, there is a great interest in the combination regimens 
such as nivolumab and ipilumimab.14 Nevertheless, the costs of targeted therapies, along with the 
costs of administration and management of adverse events, may result in a significant economic 
burden on Medicare.  
A number of studies in the past have assessed the economic burden of RCC.3,15-19 Estimates 
from previous studies on the economic burden of RCC ranged from $600 million to $5.19 billion, 
with annual per-patient medical costs between $11,169 and $43,805 (2009 USD). However, a 
majority of studies were conducted during the cytokine therapy era. Only Shih et al. (2011) 
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assessed the economic burden of RCC at the beginning of the targeted therapy era using Medicare 
data from 1991 to 2005 and MarketScan claims data from 1991 to 2007.18 The average annual 
direct medical cost among older RCC patients was $11,169. Further, costs among patients treated 
with targeted therapies were 3-5 times higher than for patients not treated with targeted therapy. 
Because Medicare Part D was not available in 2005, drug costs were assessed using Medicare 
supplemental coverage data from MarkeScan. These costs may not accurately represent the burden 
among all older patients on Medicare Part D plans. Additionally, a number of targeted therapies 
approved since 2009 were not included in this study.18 As the landscape of targeted therapies 
continues to evolve, patients are more likely to receive multiple lines of targeted therapies than 
they received in the past.20 This would increase healthcare cost to Medicare. On the other side, for 
early stage patients, use of active surveillance, advanced imaging, and minimally invasive surgical 
techniques may result in cost savings.   
The aim of this study was to assess the economic burden of RCC among older adults from 
Medicare’s perspective. The study also assessed healthcare costs by types of resources used and 
the stage at which cancer was diagnosed.  
 
METHODS 
Data Source 
SEER-Medicare 
The Surveillance Epidemiology and End Result (SEER) program, initiated by the National 
Cancer Institute (NCI), collects information on cancer statistics in an effort to reduce the cancer 
burden among the U.S population.21 The information collected by this population-based cancer 
registry includes demographics, incident cancer diagnosis, cause of death, cancer stage, tumor 
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characteristics, and surgery and radiation therapy provided during the first course of treatment. As 
of 2016, SEER registries covered 28% of the U.S population.22 Medicare data provides 
information on Part A (hospital), Part B (outpatient) and Part D (prescription drug) claims for 
Medicare beneficiaries. SEER-Medicare links SEER and Medicare data. In order to compare 
cancer patients on Medicare living in SEER regions to non-cancer patients, NCI provides a 5% 
random sample of Medicare beneficiaries with no cancer from SEER regions.21 
We used 2005-2013 SEER-Medicare linked data for RCC patients and a 5% random 
sample of non-cancer Medicare beneficiaries for controls. The Patient Entitlement and Diagnosis 
Summary File (PEDSF) was used to obtain demographics and cancer diagnosis-related 
information. Resource use and cost-related information were obtained from Medicare Provider 
Analysis and Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies 
(HHA), hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used 
to obtain inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on 
hospice care utilization. The carrier file provided information on non-institutional physician-
provided services whereas the outpatient file provided information on institutional physician-
provided services. The PDE file provided data related to prescription medication use (Medicare 
Part D). DME files provided data on the use of durable medical equipment while HHA files were 
used to get information on services provided in patients’ homes. 
Study Design and Sample Selection 
The study used a prevalence-based design to quantify the economic burden of RCC in 
2013. Patients diagnosed in 2013 and before (from 2005) were identified using ICD-O (v.3) code 
C649 and relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318').  Healthcare costs 
were examined using 2013 claims. To be included in the study, patients needed to be alive for at 
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least one month in 2013. We excluded patients aged < 65 years at the time of diagnosis, diagnosed 
with another cancer, diagnosed on autopsy, with cancer reported by death certificate, or enrolled 
in health maintenance organizations (HMOs). Control group was assigned a random date of 
pseudo-diagnosis between January 2013 to end of December 2013. Control patients aged <65 years 
at the time of pseudo-diagnosis, not continuously enrolled in Medicare, or enrolled in HMOs were 
excluded. Figure 1 depicts the sample selection process for the RCC and control groups.  
The total healthcare cost (THC) was estimated using the phase-based approach, which 
classifies patients into early, continuing and late phases of care.18, 23, 24 In this study, early phase 
included patients diagnosed in 2013 who remained alive at the end of 2013. Patients who died in 
2013 represented the late phase. Patients diagnosed before 2013 who remained alive at the end of 
2013 represented the continuing phase. A pseudo date of diagnosis and Medicare date of death 
were used to classify control patients into initial, continuing and late phases. To reduce selection 
bias, RCC patients were matched in a 1:1 ratio with control patients for each phase using 
propensity score matching (PSM). PSM was a two-step process. In the first step, the probability 
of being diagnosed with RCC was calculated using multivariable logistic regression controlling 
for age, sex, race, SEER registry, urban-rural status and NCI Comorbidity Index score. In the 
second stage, patients from RCC and control groups were matched using a greedy matching 
technique.25 The quality of matching was assessed by the distribution of propensity scores and 
comparing standardized scores for patient characteristics before and after matching. Standardized 
scores of <10% after matching indicated a good match.26, 27  
Study Measures 
Healthcare cost 
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Since this study was conducted from Medicare’s perspective, only direct medical costs to 
Medicare were included. Out of pocket costs were not included in the cost analysis. Costs were 
defined as the amounts reimbursed by Medicare for each claim. Costs were calculated for each 
type of resource used and aggregated to obtain THC. Incremental cost, which is the difference in 
the average cost of RCC and matched control patients was the costs associated with RCC. 
Incremental costs were estimated for each phase as well as for the aggregated sample.  
Other variables  
 These variables included patient demographics, urban/rural status, geographical region 
based on areas represented by SEER registry, cancer stage, histology and NCI comorbidity index. 
We used the American Joint Committee on Cancer (AJCC 6th edition) criteria to classify patients 
into stages I - IV and unknown stage.28 
RCC prevalence/number of patients 
 Identifying the number of older RCC patients in the U.S was a two-step process. In the first 
step, we calculated the number of older RCC patients living in areas represented by SEER 
registries in 2015 (diagnosed before and during 2015) using SEER Stat software.29 In the second 
step, the estimate based on SEER registries was used to derive the number of older RCC patients 
in the U.S using the Projected Prevalence (ProjPrev) Software developed by the NCI.30  
Statistical Analysis 
We compared patient characteristics between unmatched RCC and control groups using 
chi-square tests and t-tests as appropriate. After PSM, differences in characteristics were examined 
using paired t-tests and McNemar tests. Incremental costs between matched groups were 
calculated using generalized linear models controlling for age, sex, race, SEER registry, 
urban/rural status, NCI Comorbidity Score and length of the time spent in each phase of care. The 
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choice of distribution for GLMs was based on modified Park tests, while the appropriate links 
were selected based on Pearson correlation tests, Pregibon link tests, and modified Hosmer and 
Lemeshow tests. In cost categories with excess zeros (defined as ≥ 20%), two-part models were 
used. In a two-part model, the first part calculated the probability of having a positive cost. The 
second part calculated the expected mean cost. This mean cost was multiplied by the probability 
calculated in the first part to estimate the mean cost for the sample. Incremental costs were 
calculated between RCC and non-cancer controls for the overall sample and by cancer stage. While 
calculating costs by cancer stages, we compared costs for each stage to costs for non-cancer 
controls. Upon examination of the distribution of THC, we excluded observations with THC > 
$400,000 (99.9th percentile) and their matched cases or controls, which were considered as 
outliers. In addition, to account for the skewed distribution of cost data, we calculated confidence 
intervals for mean costs using a non-parametric bootstrapping method with 1000 replications. 
The total economic burden of RCC among older adults was calculated by multiplying the 
average incremental THC with the estimated number of older RCC patients in the U.S. All costs 
were inflated to 2015 USD using the Consumer Price Index for medical care services and medical 
care commodities.31 
Sensitivity Analyses 
 First, we included observations that were considered as outliers in the base-case scenario. 
Second, since comorbidities may fall into the causal pathway between RCC diagnosis and 
healthcare costs, we excluded the NCI comorbidity score from the propensity score model and re-
examined incremental costs and total economic burden. Third, we excluded covariates from the 
GLM model after matching RCC and control groups to calculate incremental costs. Fourth, we 
used GLM models using the commonly used log link and gamma distribution instead of 
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distributions and links, which were chosen based on the model fit tests. The stage of cancer in 
SEER data is determined at the first cancer diagnosis. Some of the early stage patients from 2005-
2012 may have progressed to stage-IV in 2013. Therefore, we assumed that 30% of patients 
diagnosed with earlier stages prior to 2013 may have progressed to stage-IV in 2013.32-34 Under 
this assumption, we recalculated the total economic burden among stage-IV and overall  RCC  
patients. 
 All statistical analyses were conducted at an alpha level of 0.05 using SAS v.9.4 (SAS 
Institute Inc., Cary, NC), and STATA (version 13.0, StataCorp, College Station, TX).   
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Figure 2.1. Sample selection process for Renal Cell Carcinoma and non-cancer patients in 
this study 
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RESULTS  
Sample Characteristics 
Patient characteristics for RCC and control group patients before and after matching can 
be found in Table 2.1 The sample before matching included 10,408 RCC and 170,061 control 
patients. Before matching, large differences were observed between characteristics of RCC and 
control patients. The RCC group had a lower proportion of patients (16% vs 25%) aged > 80 years, 
a higher proportion of males (56% vs 39%), and Caucasians (87% vs 83%) and a lower proportion 
of patients with zero NCI comorbidity score (53% vs 70%) than control group. 
The study sample after matching included 10,392 each of RCC and control patients. The 
magnitude of difference observed between RCC and control groups was reduced after matching. 
The average age was 74 years for RCC and 75 years for controls. RCC and control groups had a 
similar proportion of males (56% vs 59%), Caucasians (87% vs 84%) and patients with zero NCI 
comorbidity score (53% vs 51%). All standardized differences between matched groups, except 
age, were < 10%, which indicated a good match between the two groups.  
Among RCC patients, 65% were diagnosed at stage-I, 8% was diagnosed at a stage-II, 15% 
were diagnosed at stage-III, and 7% were diagnosed at stage-IV. About 81% had a clear-cell 
histology.  
Total Healthcare Cost per patient 
The annual THC per patient was $23,489 for RCC and $16,070 for the matched control 
group. The incremental THC per patient was the $7,419 for all phases combined, $22,752 for the 
initial phase, $4,860 for the continuing phase and the $13,232 for the late phase. In each phase, the 
difference in cost between the RCC and control group was significant (p < 0.05). The THC per 
patient also varied by stage at which the cancer was diagnosed. Average incremental THCs for 
patients diagnosed at stages I and II were approximately $4,700 - $5,000; whereas the average 
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incremental THCs for those diagnosed at stage-III and stage-IV were $9,331 and the $31,637 
respectively. The average THC for patients diagnosed at stage-IV was about 6-7 times higher than 
the costs for patients diagnosed at stages I and II. For patients diagnosed at stages I - III, average 
THCs and incremental costs were higher in the initial and late phases than in the continuing phase. 
However, for patients diagnosed with stage-IV (mRCC), average THCs were similar across all 
three phases of care while incremental THCs were higher in the initial and continuing phases than 
the late phase. Details of costs for RCC and control group patients by a phase of care and stage at 
diagnosis can be found in Table 2.2  
Total Economic Burden of RCC on Medicare 
 Based on the SEER Stat analysis, there were 18,121 older RCC patients alive in areas 
covered by SEER registries in 2015. The projected count of older RCC patients in the U.S. 
calculated using ProjPrev was 204,256. Multiplying the incremental cost of RCC by the projected 
number of RCC patients resulted in the total economic burden of $1,52 billion. To calculate 
economic burden by stages, we first calculated the number of RCC patients at various stages of 
diagnosis by assuming a distribution similar to SEER data. The total economic burden was 
estimated to be $524 million for stage-I, $68 million for stage-II, $267 million for stage-III, $1.0 
billion for stage-IV and $166 million for the unknown stage. The weighted total economic burden 
of RCC was found to be  $2.06 billion. 
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Table 2.1 Characteristics of Renal Cell Carcinoma and non-cancer patients in this study.  
Characteristics RCC 
(n = 10,408) 
n, (%) 
Non-cancer 
(n = 170,061) 
n, (%) 
RCC  
(matched) 
(n = 10,392) 
n, (%) 
Non-cancer 
(matched) 
(n = 10,392) 
n, (%) 
Standardized 
difference  
after matching 
Age (mean, SD) * + 73.8 (6.3) 75.5 (7.3) 73.8 (6.3) 74.9 (7.1) 0.1645 
Age categories (year) * + 
- 65 to 69  
- 70 to 74   
- 75 to 79  
- 80 and older 
 
3,225 (31.0) 
 3,486 (33.5) 
 2,003 (19.2) 
1,694 (16.3) 
 
43,043 (25.3) 
 52,207 (30.7) 
32,763 (19.3) 
42,048 (24.7) 
 
3,216 (31.0) 
3,479 (33.5) 
2,003 (19.3) 
1,694 (16.3) 
 
 2,883 (27.7) 
3,251 (31.3) 
1,995 (19.3) 
2,263 (21.8) 
 
0.0705 
0.0468 
0.0017 
0.1397 
Gender (% Male) *  + 5,863 (56.3) 65,978 (38.8) 5,850 (56.3) 6,162 (59.3) 0.0608 
Race (%) *  + 
- Caucasian 
- Black 
- Others 
 
  9,000 (86.5) 
 815 (7.8) 
 593 (5.7) 
 
140,757 (82.8) 
 12,063 (7.1) 
17,241 (10.1) 
 
8,989 (86.5) 
812 (7.8) 
591 (5.7) 
 
8,756 (84.3) 
1,013 (9.8) 
623 (6.0) 
 
0.0629 
0.0680 
0.0127 
NCI  Comorbidity Index 
Score (mean, SD) * + 
0.5 (1.0) 0.9 (1.4) 0.9 (1.3) 1.0 (1.4) 0.0582 
NCI  Comorbidity  Index 
Score categories * + 
  - 0  
  - 1 to 2 
  - 3 or more 
 
 
5,469 (52.6) 
3,685 (35.4) 
1,254 (12.1) 
 
 
11,9240 (70.1) 
41,956 (24.7) 
8,865 (5.2) 
 
 
5,468 (52.6) 
3,682 (35.4) 
1,242 (11.9) 
 
 
5,283 (50.8) 
3,725 (35.8) 
1,384 (13.3) 
 
 
0.0358 
0.0086 
0.0413 
Urban /Rural (%)  
- Big Metro 
- Metro 
- Urban  
- Less urban 
- Rural 
 
  5,295 (50.9) 
3,161 (30.4) 
 683 (6.6) 
1,018 (9.8) 
251 (2.4) 
 
87,713 (51.6) 
 51,905 (30.5) 
 10,902 (6.4) 
15,834 (9.3) 
3,707 (2.2) 
 
5,289 (50.9) 
 3,153 (30.4) 
682 (6.6) 
1,017 (9.8) 
251 (2.4) 
 
4,856 (46.7) 
3,289 (31.6) 
822 (7.9) 
1,172 (11.3) 
253 (2.4) 
 
0.0830 
0.0280 
0.0520 
0.0483 
0.0013 
SEER region *  
- North East 
- South 
- North Central 
- West 
 
2,042 (19.6) 
2,823 (27.1) 
1,246 (12.0) 
4,297 (41.3) 
 
33,885 (19.9) 
40,345 (23.7) 
19,078 (11.2) 
76,753 (45.1) 
 
2,040 (19.6) 
2,818 (27.1) 
1,245 (12.0) 
4,289 (41.3)  
 
2,076 (20.0) 
2,743 (26.4) 
1,242 (12.0) 
4,331 (41.7) 
 
0.0087 
0.0163 
0.0001 
0.0082 
Phase of Care  
- Initial Phase 
- Continuing Phase 
- Late Phase  
 
1,779 (17.1) 
7,806 (75.0) 
823 (7.9) 
 
24,580 (14.5) 
138,112 (81.2) 
7,369 (4.3) 
 
1,778 (17.1)  
7,794 (75.0) 
820 (7.9) 
 
1,777 (17.1)  
7,794 (75.0) 
821 (7.9) 
 
NA 
Cancer Stage 
- Stage I 
- Stage II 
- Stage III 
- Stage IV 
- Unknown 
 
6,720 (64.6) 
784 (7.5) 
1554 (14.9) 
756 (7.3) 
594 (5.7) 
 
NA 
 
6,710 (64.6) 
782 (7.5) 
1,551 (14.9) 
755 (7.3) 
594 (5.7)  
 
NA 
 
NA 
Histology 
- Clear cell 
- Non-clear cell 
 
8,455 (81.2) 
1,953 (18.8) 
 
NA 
 
8,443 (81.3) 
1,949 (18.8) 
 
NA 
 
NA 
Note: NA: not applicable; * Difference was statistically significant (p <0.05) before matching; +: difference was 
statistically significant after matching 
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Table 2.2 Annual total healthcare cost associated with Renal Cell Carcinoma by disease 
phase and by stage at which cancer was diagnosed 
 
Cancer stage at 
diagnosis 
RCC  
(US $) 
(mean, 95%CI) 
Matched Non-Cancer 
(US $) 
(mean, 95%CI) 
Incremental Cost  
(US $) 
(mean, 95%CI) 
Any Stage (n = 20,784)    
All phases  23,489 (22,805 - 24,174) 16,070 (15,507 - 16,633)    7,419 (6,553- 8,285)* 
Initial   32,669 (31,109 - 34,229)    9,917 (8,911 - 10,923)    22,752 (20,875 - 24,629)*     
Continuing  18,939 (18,226 - 19,652)  14,078 (13,525 - 14,631)  4,860 (3,965 - 5,756)*  
Late phase  54,983 (51,790 - 58,176)  41,750 (38,737 - 44,764) 13,232 (9,015 - 17,450)* 
Stage- I (n = 17,102) 
All phases  20,528 (19,749 - 21,306) 15,944 (15,385 - 16,504) 4,584 (3,652 - 5,515)* 
Initial  29,073 (27,113 - 31,033)     9,942 (8,925 - 10,959)      19,131 (16,905 - 21,356)*     
Continuing 17,210 (16,408 - 18,012)  14,150 (13,574 - 14,725)    3,060 (2,044 - 4,077)* 
Late phase 52,314 (46,565 - 58,063)   43,006 (39,798 - 46,214) 9,307 (2,755 - 15,860)* 
Stage - II (n = 11,174) 
All phases  20,671 (18,407 - 22,936)   15,944 (15,385 - 16,504) 4,727 (2,418 - 7,037)*  
Initial  33,417 (26,976 - 39,859) 9,926 (8,922 - 10,930) 23,491 (17,112 - 29,870)* 
Continuing 16,403 (14,107 - 18,699)  14,226 (13,660 - 14,793)  2,177 (-208 - 4,561) 
Late phase 52,068 (37,575 - 66,560)   43,196 (39,847 - 46,545) 6,398 (-6,125 - 23,868) 
Stage - III (n = 11,943) 
All phases 25,275 (23,524 - 27,027) 15,944 (15,385 - 16,504) 9,331 (7,505 - 11,157)* 
Initial  36,489 (31,738 - 41,241) 9,879 (8,874 - 10,884) 26,610 (21,756 - 31,464)* 
Continuing 20,946 (19,038 - 22,854) 14,190 (13,624 - 14,756) 6,756 (4,783 - 8,729)* 
Late  57,923 (50,237 - 65,610) 42,966 (39,752 - 46,181) 14,957 (6,701 - 23,213)* 
Stage- IV (n = 11,147) 
All phases 47,581 (44,217 - 50,946) 15,944 (15,385 - 16,504) 31,637 (28,220 - 35,054)* 
Initial  50,805 (44,477 - 57,133) 9,862 (8,892 - 10,832)    40,943 (34,530 - 45,357)* 
Continuing 46,546 (40,344 - 52,749) 14,250 (13,678 - 14,823) 32,296 (26,064 - 38,528)* 
Late  62,008 (55,880 - 68,135) 41,647 (38,500 - 44,795)    20,360 (13,571 - 27,150)* 
Stage- Unknown (n = 10,986) 
All phases  27,579 (24,562 - 30,597) 15,944 (15,385 - 16,504) 11,635 (8,559 - 14,712)* 
Initial  35,026 (26,059 - 43,992) 10,014 (8,953 - 11,076) 25,011 (15,908 - 34,115)* 
Continuing 22,971 (19,534 - 26,408) 14,258 (13,691 - 14,825) 8,713 (5,229 - 12,198)* 
Late  59,415 (46,816 - 72,013) 42,398 (39,238 - 45,557) 17,017 (4,309 - 29,725)* 
* statistically significant difference (p-value < 0.05) 
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Healthcare Costs by Types of Services Used 
RCC patients had significantly higher costs than controls for all types of resources used 
except for DME and SNF. For RCC patients, costs related to hospitalizations ($2,282 per patient), 
hospital outpatient use ($1,497 per patient) and physician-provided services ($ 1,544 per patient) 
were the top three drivers of  THC.  
Among stage-I RCC patients, the cost associated with hospital use, outpatient services, 
physician-provided services, prescription drugs and hospice care services were significantly (p-
value <0.05) higher than control group patients. Costs associated with hospital use, outpatient 
services and physician provided care were the top three drivers of THC. A similar pattern was 
observed for stage-II and stage-III patients. However, THC incurred among patients with stage III 
were ~ 2 times the costs for stages I and II. For stages, I - III, costs associated with hospice care, 
DME, SNF and home health services did not differ significantly from controls. Patients diagnosed 
at stage-IV (mRCC) exhibited a different distribution of cost drivers compared to patients 
diagnosed at earlier stages. For patients diagnosed at stage-IV, incremental costs were ~ 9 times 
higher than patients from stages I and II and ~ 4 times higher than stage-III patients. For mRCC 
patients, prescription drug cost ($11,747) was the largest component of  THC. Unlike patients from 
earlier stages, stage-IV patients had significantly (p<0.05) higher home health and hospice care 
costs than control group patients. Details regarding costs by types of resources used and cancer 
stages are described in Table 2.3  
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Table 2.3 Healthcare cost by types of resources used and cancer stage at diagnosis 
 RCC  
 (mean, 95%CI) 
Matched Non-Cancer  
(mean, 95%CI) 
Incremental Cost  
 (mean, 95%CI) 
Any Stage (n = 20,784) 
Total  23,489 (23,141 - 24,511) 16,070 (15,178 - 16,289)     7,419 (6,553 - 8,285)* 
Hospital  4,830 (4,564 - 5,095) 2,548 (2,320 - 2,776)    2,282 (1,929 - 2,634)* 
ED  4,709 (4,455 - 4,964) 3,899 (3,648 - 4,150) 811 (461 - 1,161)* 
Skilled nursing facility 1,503 (1,372 - 1,634) 1,405 (1,278 - 1,532) 98 (-80 - 276)  
Outpatient services 3,053 (2,902 - 3,204) 1,556 (1,469 - 1,644) 1,497 (1,327 - 1,666)* 
Physician services 4,419 (4,288 - 4,551) 2,875 (2,801 - 2,976) 1,544 (1,385 - 1,704)* 
Prescription drugs 3,817 (3,538 - 4,097) 2,169 (2,067 - 2,272) 1,648 (1,352 - 1,944)* 
DME 232 (215 - 250) 247 (225 - 268) -14 (-38 - 10) 
Hospice care 723 (627 - 818) 551 (469 - 634) 172 (51 - 292)* 
Home health 818 (771 - 866) 691 (645 - 737) 127 (63 - 192)* 
Stage - I (n = 17,102) 
Total  20,528 (19,749 - 21,306) 15,944 (15,385 - 16,504) 4,584 (3,652 - 5,515)* 
Hospital  4,417 (4,096 - 4,738) 2,543 (2,316 - 2,770)    1,917 (1,532 - 2,301)* 
ED  4,204 (3,892 - 4,516) 3,855 (3,607 - 4,103) 350 (-33 - 732) 
Skilled nursing facility 1,356 (1,202 - 1,510) 1,411 (1,284 - 1,538)  -55 (-251 - 142) 
Outpatient services 2,710 (2,535 - 2,885) 1,561 (1,473 - 1,649) 1,149 (955 - 1,343)* 
Physician services 3,987 (3,849  -  4,125) 2,873 (2,786 - 2,961) 1,114 (949 - 1,278)* 
Prescription drugs 2,458 (2,299 - 2,617) 2,279 (2,160 - 2,398) 179 (-19 - 377) 
DME 223 (205 - 242) 246 (225 - 268) -23 (-49 - 3) 
Hospice care 393 (309 - 477) 580 (493 - 667) -187 (-304, -69)* 
Home health 746 (690 - 803) 695 (648 - 741) 52 (-20 - 123) 
Stage- II (n = 11,174) 
Total  20,671 (18,407 - 22,936)   15,944 (15,385 - 16,504) 4,727 (2,418 - 7,037)*  
Hospital  4,128 (3,313 - 4,943)      2,543(2,316 - 2,770)    1,585 (747 - 2,424)*    
ED  4,390 (3,304 - 5,478) 3,855 (3,607 - 4,103) 536 (-573 - 1,646) 
Skilled nursing facility 1,267 (827 - 1,707)    1,411 (1,284 - 1,538) -144 (-600 - 313) 
Outpatient services 2,394 (1,950 - 2,838) 1,561 (1,473 - 1,649) 833 (381 - 1,825)* 
Physician services 3,830 (3,409 - 4,252) 2,873 (2,786 - 2,961) 957 (492 - 1,360)* 
Prescription drugs 3,522 (2,456 - 4,588) 2,279 (2,160 - 2,398) 1,243 (183 - 2,304) 
DME 256 (167 - 343) 246 (225 - 268) 9 (-81 - 99) 
Hospice care 701 (350 - 1052) 580 (493 - 667) 121 (-238 - 480) 
Home health 763 (602 - 8923) 695 (648 - 741) 68 (-98 - 234) 
Stage- III (n = 11,943) 
Total  25,275 (23,524 - 27,027) 15,944 (15,385 - 16,504) 9,331 (7,505 - 11,157)* 
Hospital  5,896 (5,141 - 6,652) 2,543 (2,316 - 2,770)    3,353 (2,564 - 4,142)* 
ED  4,733 (4,099 - 5,364)    3,855 (3,607 - 4,103) 878 (183 - 1,574)* 
Skilled nursing facility 1,323 (1,036 - 1,610)    1,411 (1,284 - 1,538) -88 (-405 - 229) 
Outpatient services 3,387 (2,991 - 3,784) 1,561 (1,473 - 1,649) 1,826 (1,424 - 2,228)* 
Physician services 4,982 (4,568 - 5,396) 2,873 (2,786 - 2,961) 2,109 (1,686 - 2,532)* 
Prescription drugs 4,330 (3,503 - 5,158)    2,279 (2,160 - 2,398) 2,052 (1,218 - 2,886)* 
DME 213 (176 - 249) 246 (225 - 268) -34 (-73 - 5) 
Hospice care 821 (552 - 1,089) 580 (493 - 667) 241 (-38 - 519) 
Home health 909 (782 - 1,036) 695 (648 - 741) 215 (80 - 349)* 
* Statistically significant differences, p < 0.05 
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Table 2.3 (continued) 
 RCC  
 (mean, 95%CI) 
Matched Non-Cancer  
(mean, 95%CI) 
Incremental Cost  
 (mean, 95%CI) 
Stage- IV (n = 11,147) 
Total  47,581 (44,217 - 50,946) 15,944 (15,385 - 16,504) 31,637 (28,220 - 35,054)* 
Hospital  5,574 (4,586 - 6,562) 2,543 (2,316 - 2,770)    3,031 (2,009 - 4,053)* 
ED  7,532 (6,490 - 8,574) 3,855 (3,607 - 4,103) 3,677 (2,591 - 4,764)* 
Skilled nursing facility 2,266 (1,689 - 2,842) 1,411 (1,284 - 1,538) 855 (274 - 1,435)* 
Outpatient services 6,685 (5,840 - 7,530)  1,561 (1,473 - 1,649) 5,124 (4,280 - 5,968)* 
Physician services 8,061 (7,306 - 8,816) 2,873 (2,786 - 2,961) 5,188 (4,422 - 5,953)* 
Prescription drugs 14,026 (11,530 - 16,522)  2,279 (2,160 - 2,398) 11,747 (9,258 - 14,237)*  
DME 279 (200 - 357) 246 (225 - 268) 32 (-46 - 111) 
Hospice care 2,457 (1,877 - 3,036) 580 (493 - 667) 1,877 (1,298 - 2,455)* 
Home health 1,374 (990 - 1,387) 695 (648 - 741) 680 (448 - 912)* 
Stage-Unknown (n = 10,986) 
Total  27,579 (24,562 - 30,597) 15,944 (15,385 - 16,504) 11,635 (8,559 - 14,712)* 
Hospital  4,259 (3,172 - 5,347) 2,543(2,316 - 2,770)    1,716 (598 - 2,835)*    
ED  6,323 (5,237 - 7,409)     3,855 (3,607 - 4,103) 2,468 (1,352 - 3,585)*    
Skilled nursing facility 2,614 (1,936 - 3,291)   1,411 (1,284 - 1,538) 1,203 (514 - 1,892)*    
Outpatient services 3,002 (2,470 - 3,534) 1,561 (1,473 - 1,649) 1,441 (903 - 1,979)* 
Physician services 4,506 (4,046 - 4,967) 2,873 (2,786 - 2,961) 1,633 (1,165 - 1,984)* 
Prescription drugs 3,865 (2,573 - 5,157)    2,279 (2,160 - 2,398) 1,586 (278 - 2,895)* 
DME 301 (217 - 384) 246 (225 - 268) 54 (-32 - 140) 
Hospice care 1,337 (834 - 1,839)    580 (493 - 667) 757 (251 - 1,262)* 
Home health 849 (661 - 1,037) 695 (648 - 741) 155 (-41 - 350) 
    * Statistically significant difference, p < 0.05  
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Sensitivity Analyses 
 The average THC changed by only a small magnitude (less than 1 to 2%) in the unadjusted 
analysis and after including outliers. When NCI-comorbidity score was excluded from the 
propensity score model, the incremental cost per person increased by 45% from $7,419 to $10,770. 
The total economic burden on Medicare increased from $1.5 billion to $1.8 billion. The THC for 
mRCC increased by 10%. The use of log link and gamma distribution in a GLM resulted in a 4% 
increase in the average THC and total economic burden on Medicare. Under the assumption that 
about 30% of patients diagnosed before 2013 at earlier stages progressed to a metastatic stage, the 
estimated economic burden of RCC was $3.3 billion and among metastatic patients was $2.5 
billion. Details regarding sensitivity analyses are described in Table 2.4 
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Table 2.4 Results from sensitivity analyses 
 Incremental cost per patient (US $) Total economic burden (US $) 
 Any 
stage 
Change from 
base case 
Stage-
IV 
Change 
from base 
case 
Any stage Change from 
base case 
Stage-IV Change 
from base 
case 
Base case 7,419 NA 31,637 NA 1.51 billion NA 1.03 billion NA 
Including potential outliers 7,330 -1.20% 31,458 -0.6% 1.50 billion -1.20% 1.03 billion -0.6% 
Excluding NCI comorbidity 
index score from matching 
10,770 + 45.17% 34,880 +10.25% 2.20 billion + 45% 1.14 billion +10.25% 
Excluding covariates from 
the regression after matching 
7,274 -1.95% 31,013 -1.97% 1.49 billion -1.95% 1.01 billion -1.97% 
GLM with log link and 
Gamma distribution 
7,739 +4.31% 31,235 -1.27% 1.58 billion +4.31% 1.02 billion -1.27% 
Assume that 30% from 
earlier stages and diagnosed 
before 2013 may have 
reached to advanced stage in 
2013 ** 
7,419 NA 31,637 NA 3.34 billion +120.39% 2.53 billion +145.14% 
 
NA: not applicable, ** average costs were considered same as main analysis but the number of RCC patients varied. 
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DISCUSSION 
This study assessed the economic burden of RCC from Medicare’s perspective. We used 
the most recent SEER-Medicare data to reflect the economic burden in the later part of the targeted 
therapy era (2009-2013). This was also the first study among older adults, in this era, to assess 
drivers of healthcare costs for patients diagnosed at different stages. The average THC associated 
with RCC was $7,419 while the total economic burden was estimated to be $1.52 billion. Due to 
a higher prevalence of patients diagnosed at stage-I, costs associated with stage-I were the largest 
component of the total economic burden. However, in terms of average THC, patients diagnosed 
at stage-IV had the highest costs compared with patients diagnosed at earlier stages.  
The average THC estimate from our study was similar, although slightly lower than the 
estimate of $11,169 from a study by Shih et al. Some methodological differences may explain 
slightly lower costs in our study. Shih et al. used frequency matching to match RCC and control 
patients on patient demographics; while we used propensity scores calculated using patient 
demographics and NCI comorbidity index. In a sensitivity analysis, matching only on 
demographics resulted in a similar cost estimate ($10,770) than the estimate from Shih et al.18  
The total economic burden of RCC (estimated at $1.5 - $3 billion) in our study was lower 
than the economic burden of RCC projected by Mariotto et al ($4 - $6 billion) in the cytokine era.17 
Several reasons could explain the differences. First, we included only the most common histologies 
of RCC, while Mariotto et al estimated costs for all forms of kidney cancers. Second, we used 
PSM where propensity scores were based on demographics and NCI comorbidity index as opposed 
to matching only on age and gender. Third, several changes occurred in the management of RCC 
over the last decade. While approval of several targeted therapies may have resulted in an increase 
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in THC for stage-IV patients, uptake of less invasive surgical procedures and active surveillance 
among early stage patients could have resulted in lower healthcare costs. 
The pattern of THC by phases of care was similar to previous studies. THC was highest in 
the initial phase during which patients undergo screening, receive aggressive cancer-related 
treatment and require monitoring and treatment of adverse events and complications. THC was 
lowest in the continuing phase, a phase where patients often have a remission and require minimal 
follow-up care. THC in the late phase was higher than the continuing phase but lower than the 
initial phase of care. 18, 23 Other Studies published using a phase of care approach have found that 
THC was highest in the late phase of care. A different pattern of THC for the late phase of care in 
our study could be due matching on comorbidities and/or differences in the operational definition 
of the phase of care. Because stage-IV patients have a shorter survival compared to patients 
diagnosed at earlier stages, their costs were similar across all three phases. 
 In our study, the costs among mRCC patients were about 9 times higher than patients 
diagnosed at stages- I and II. In addition, the average cost for stage-IV patients was approximately 
$28,000 more than the average cost for early stage patients. In contrast, during the cytokine era, 
Hollenbeak et al. found that 1-year cost among patients with distant metastasis was $4,482 higher 
(2 times higher) than costs among patients with localized disease3 and Lang et al. estimated that 
the average cost for metastatic patients ($26,573) was lower than the average cost for localized 
disease ($36,968), which was surprising considering the aggressive treatment given among 
patients with the metastatic stage.16 Our findings suggest that although the life expectancy among 
mRCC patients increased in the targeted therapy era, it also resulted in higher costs for stage-IV 
patients. For patients diagnosed at stages-I to III, hospital cost was the largest component (~ 40%) 
of THC. Higher costs related to hospital use may indicate the use of partial or complete 
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nephrectomy, laparoscopic surgery and local therapies such as radiofrequency ablation which are 
primarily used to treat early stage, localized tumor and require hospitalization. Services provided 
by physicians and other healthcare professionals in hospitals and noninstitutional physician offices 
were the next largest components (5% each) of THC for these patients. Smaller or non-significant 
differences in the costs for the use of ED, DME, prescription drugs, hospice care, and home health 
services suggested that patients diagnosed at stages I and II may use these services no more often 
than matched non-cancer patients. THC among stage-III patients was about two times higher than 
costs for stages-I and II, which could be due to an advanced form of the disease and relatively 
aggressive form of treatment. In contrast to patients diagnosed at stage-I and II, prescription drug 
costs among those diagnosed at stage-III was significantly higher than control patients. This could 
be due to the use of systemic therapy in patients with recurrent disease or adjuvant use after 
nephrectomy. For stage-IV patients, prescription drug costs accounted for 36% of THC, which 
suggest the use of high-cost targeted therapies and medications given to control complications 
arising at the site of metastasis (eg. bisphosphonates for bone metastases). In addition to 
prescription drugs, costs associated with ED use were substantially high among mRCC patients 
and accounted for 12% of THC. Costs associated with hospice care and skilled nursing home 
facility use were much higher for mRCC patients than patients with earlier stages, which suggests 
the extensive use of nursing and palliative care among stage-IV patients.  
This study has several limitations. We used PSM to reduce selection bias and make RCC 
and control groups similar in patient characteristics. However, we could not match on factors that 
were not observed in the SEER-Medicare data such as performance status. Second, while 
projecting the total economic burden to the entire Medicare population of age ≥ 65 years, we 
assumed that patients on managed care plans have the same costs as patients from fee-for service 
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(FFS) plans. While it was necessary to exclude patients from managed care plans due to 
unavailability of their Part A and Part B claims in the SEER-Medicare data, average costs among 
managed care patients may differ from patients on FFS plans. This may result in under or over-
estimation of the total economic burden. Due to unavailability of the data after 2013, the study did 
not include newer targeted therapies such as cabozantinib, approved in 2016. The SEER data 
measures cancer stage only at the time of first cancer diagnosis. Hence, the prevalence of RCC by 
stage was calculated based on the initial staging information, which may not be the most recent 
staging information. According to the literature about 30-33% of patients diagnosed at earlier 
stages eventually progress to the metastatic stage.32, 33 It is, therefore, possible that we 
underestimated prevalence and total economic burden of mRCC. Lastly, the use of administrative 
claims and registry data are subject to miscoding errors. 
Despite these limitations, our study provided important information on the economic 
burden of RCC and drivers of the THC for patients diagnosed at various stages. Several targeted 
and immunotherapies have been approved recently to treat mRCC. In addition, targeted therapies 
are currently being studied among locally advanced (stage-III) patients as adjuvant therapies. This 
study may provide a baseline that can be used to evaluate the value of emerging therapies among 
older RCC patients.   
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Appendix for study 1 
Appendix 2.1 Characteristics of Renal Cell Carcinoma and non-cancer patients before and 
after propensity score matching - all phases combined 
Characteristic RCC 
(n = 
10,408) 
Non-
cancer 
(n = 
170,061) 
Standardize
d differences 
before 
matching 
RCC 
(matched) 
(n = 
10,397) 
Non-cancer 
(matched) 
(n = 10,397) 
Standardize
d differences 
after (1:1) 
matching 
Age at diagnosis  73.8 (6.3) 75.5 (7.3) 0.2872 73.8 (6.3) 74.9 (7.1) 0.1645 
Age categories (year) * + 
- 65 to 69  
- 70 to 75   
- 76 to 80  
   - > than 80 
 
31.0 
 33.5 
 19.2 
16.3 
 
25.3 
 30.7 
19.3 
24.7 
 
0.1264 
0.0599 
0.0005 
0.2104 
 
31.0 
33.5 
19.3 
16.3 
  
 27.7 
31.3 
19.3 
21.8 
 
0.0705 
0.0468 
0.0017 
0.1397 
Gender (% Male) 56.3 38.8 0.3567 56.3 59.3 0.0608 
Race (%) 
- Caucasian 
- Black 
- Others 
 
86.5 
7.8 
5.7 
 
82.8 
7.1 
10.1 
 
0.1028 
0.0281 
0.1650 
 
86.5 
7.8 
5.7 
 
84.3 
9.8 
6.0 
 
0.0629 
0.0680 
0.0127 
CCI (mean) 0.5 (1.0) 0.9 (1.4) 0.3654 0.9 (1.3) 1.0 (1.4) 0.0582 
Urban /Rural (%) 
- Big Metro 
- Metro 
- Urban  
- Less urban 
- Rural 
 
50.9 
30.4 
6.6 
9.8 
2.4 
 
51.6 
30.5 
6.4 
9.3 
2.2 
 
0.0141 
0.0033 
0.0061 
0.0160 
0.0155 
 
50.9 
30.4 
6.6 
9.8 
2.4 
 
46.7 
31.6 
7.9 
11.3 
2.4 
 
0.0830 
0.0280 
0.0520 
0.0483 
0.0013 
Registry (%) 
- S. Francisco 
- Connecticut 
- Detroit 
- Hawaii 
- Iowa 
- N Mexico 
- Seattle 
- Utah 
- Atlanta 
- San Jose 
- Los Angeles 
- Greater Cali 
- Kentucky 
- Louisiana 
- New Jersey 
- Georgia 
 
3.1 
5.6 
5.5 
1.2 
6.4 
2.7 
5.3 
1.9 
2.6 
2.3 
6.3 
18.5 
8.2 
7.7 
14 
8.6 
 
3.8 
5.7 
5.5 
1.3 
5.7 
2.8 
5.4 
2.2 
2.8 
2.6 
7.5 
19.5 
6.7 
5.8 
14.3 
8.4 
 
0.0408 
0.0025 
0.0031 
0.0114 
0.0286 
0.0114 
0.0038 
0.0186 
0.0097 
0.0193 
0.0436 
0.0264 
0.0572 
0.0755 
0.0071 
0.0058 
 
3.1 
5.6 
5.5 
1.2 
6.4 
2.7 
5.3 
1.9 
2.6 
2.3 
6.3 
18.5 
8.2 
7.7 
14.0 
8.6 
 
1.9 
5.7 
5.7 
1.6 
6.3 
3.8 
4.5 
1.8 
1.3 
3.4 
6.0 
18.7 
7.3 
10.5 
14.3 
7.3 
 
0.0755 
0.0029 
0.0058 
0.0358 
0.0067 
0.0663 
0.0393 
0.0100 
0.0941 
0.0641 
0.0132 
0.0054 
0.0367 
0.0990 
0.0080 
0.0469 
NOTE: Values in bold indicate reduction in standardized differences 
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Appendix -2.2 Characteristics of Renal Cell Carcinoma and non-cancer patients before and 
after propensity score matching - initial phase 
Characteristic RCC 
(N = 
10,408) 
Non-cancer 
(N = 
170,061) 
Standardized 
differences 
before 
matching 
RCC 
(matched) 
(N = 1,777) 
Non-cancer 
(matched) 
(N = 1,777) 
Standardized 
differences 
after (1:1) 
matching 
Age at diagnosis  73.8 (6.6) 75.9 (7.9) 0.2872 73.8 (6.6) 74.2 (7.1) 0.0530 
Age categories 
- 65 to 69  
- 70 to 75   
- 76 to 80  
- > than 80 
 
31.3 
32.8 
19.1 
16.9 
 
25.5 
 29.8 
17.4 
16.9 
 
0.1283 
0.0651 
0.0424 
0.2536 
 
31.3 
32.8  
19.1 
16.9 
 
30.7 
34.4 
16.1 
18.8 
 
0.0121 
0.0333 
0.0768 
0.0499 
Gender (Male %) 62.0 40.6 0.4378 62.0 62.0 0.0608 
Race (%) 
- Caucasian 
- Black 
- Others 
 
85.4 
8.8 
5.8 
 
81.2 
7.8 
11.0 
 
0.1141 
0.0369 
0.0190 
 
85.4 
8.8 
5.8 
 
84.5 
10.1 
5.4 
 
0.0267 
0.0461 
0.0171 
CCI 1.1 (1.5) 0.6 (1.2) 0.3654 1.1 (1.5) 1.2 (1.6) 0.0233 
Urban /Rural (%) 
- Big Metro 
- Metro 
- Urban  
- Less urban 
- Rural 
 
50.4 
31.0 
6.3 
9.0 
2.1 
 
51.7 
31.0 
6.2 
9.0 
2.1 
 
0.0246 
0.0005 
0.0190 
0.0255 
0.0002 
 
50.4 
31.0 
6.7 
9.7 
2.1 
 
50.8 
31.0 
6.6 
9.2 
2.4 
 
0.0067 
0.0012 
0.0023 
0.0173 
0.0188 
Registry (%) 
- S. Francisco 
- Connecticut 
- Detroit 
- Hawaii 
- Iowa 
- N Mexico 
- Seattle 
- Utah 
- Atlanta 
- San Jose 
- Los Angeles 
- Greater Cali 
- Kentucky 
- Louisiana 
- New Jersey 
- Georgia 
 
3.6 
4.3 
5.7 
1.2 
6.0 
2.9 
5.2 
2.2 
2.0 
3.0 
5.9 
18.8 
8.7 
7.8 
14.3 
8.5 
 
3.9 
5.3 
5.5 
1.3 
5.6 
2.9 
5.5 
2.1 
3.0 
2.7 
7.6 
20.0 
6.7 
5.6 
13.7 
8.6 
 
0.0143 
0.0430 
0.0123 
0.0124 
0.0135 
0.0013 
0.0125 
0.0053 
0.0658 
0.0152 
0.0717 
0.0306 
0.0751 
0.0880 
0.0182 
0.0036 
 
3.6 
4.3 
5.7 
1.2 
6.0 
2.9 
5.2 
2.2 
2.0 
3.0 
5.9 
18.8 
8.7 
7.8 
14.3 
8.5 
 
3.8 
4.3 
5.8 
1.1 
5.2 
2.8 
4.8 
2.1 
1.6 
3.1 
5.9 
19.1 
9.3 
7.6 
16.30 
7.0 
 
0.0119 
0.0000 
0.0024 
0.0107 
0.0318 
0.0034 
0.0206 
0.0038 
0.0253 
0.0065 
0.0023 
0.0086 
0.0215 
0.0063 
0.0546 
0.0547 
NOTE: Values in bold indicate reduction in standardized differences 
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Appendix 2.3 Characteristics of Renal Cell Carcinoma and non-cancer patients before and 
after propensity score matching – continuing phase 
Characteristic RCC 
(N = 
10,408) 
Non-
cancer 
(N = 
170,061) 
Standardize
d differences 
before 
matching 
RCC 
(matched) 
(N = 7,794) 
Non-cancer 
(matched) 
(N = 7,794) 
Standardized 
differences after 
(1:1) matching 
Age at diagnosis  73.4 (6.1) 75.1 (7.0) 0.2573 73.4 (6.1) 74.8 (7.0) 0.2128 
Age categories 
- 65 to 69  
- 70 to 75   
- 76 to 80  
- > than 80 
 
32.2 
34.4 
18.9 
14.5 
 
26.2 
31.7 
19.6 
22.6 
 
0.1316 
0.0584 
0.0168 
0.2083 
 
32.2 
34.4 
18.9 
14.5 
 
30.7 
34.4 
19.6 
21.5 
 
0.0927 
0.0714 
0.0166 
0.1814 
Gender (male 
%) 
55.0 38.5 0.4379 55.0 58.9 0.0608 
Race (%) 
- Caucasian 
- Black 
- Others 
 
86.5 
7.6 
5.9 
 
83.0 
7.0 
10.0 
 
0.1142 
0.0368 
0.1904 
 
86.5 
7.6 
5.9 
 
83.5 
10.0 
6.5 
 
0.0267 
0.0461 
0.0171 
CCI 0.8 (1.3) 0.5 (0.9) 0.3475 0.8 (1.2) 0.9 (1.3) 0.0820 
Urban /Rural (%) 
- Big Metro 
- Metro 
- Urban  
- Less urban 
- Rural 
 
51.4 
30.3 
6.4 
9.4 
2.4 
 
51.7 
30.4 
6.4 
9.3 
2.2 
 
0.0246 
0.0005 
0.0190 
0.0254 
0.0002 
 
51.4 
30.3 
6.4 
9.4 
2.4 
 
45.7 
32.1 
8.2 
11.7 
2.3 
 
0.0067 
0.0012 
0.0022 
0.0172 
0.0188 
Registry (%) 
- S. Francisco 
- Connecticut 
- Detroit 
- Hawaii 
- Iowa 
- N Mexico 
- Seattle 
- Utah 
- Atlanta 
- San Jose 
- Los Angeles 
- Greater Cali 
- Kentucky 
- Louisiana 
- New Jersey 
- Georgia 
 
3.0 
6.1 
5.6 
1.2 
6.3 
2.6 
5.4 
1.7 
2.7 
2.3 
6.3 
18.2 
8.1 
7.6 
14.2 
8.7 
 
3.8 
5.7 
5.4 
1.3 
5.7 
2.8 
5.4 
2.2 
2.7 
2.6 
7.4 
19.5 
6.7 
5.8 
14.4 
8.4 
 
0.0143 
0.0430 
0.0122 
0.0123 
0.0135 
0.0013 
0.0124 
0.0052 
0.0658 
0.0152 
0.0717 
0.0305 
0.0751 
0.0879 
0.0181 
0.0035 
 
3.0 
6.1 
5.6 
1.2 
6.3 
2.6 
5.4 
1.7 
2.7 
2.3 
6.3 
18.2 
8.1 
7.6 
14.2 
8.7 
 
1.5 
6.2 
5.6 
1.8 
6.5 
4.3 
4.3 
1.5 
1.1 
3.7 
6.0 
18.5 
6.4 
11.4 
14.0 
7.4 
 
0.0118 
0.0000 
0.0024 
0.0106 
0.0318 
0.0034 
0.0206 
0.0038 
0.0253 
0.0065 
0.0024 
0.0086 
0.0216 
0.0063 
0.0546 
0.0546 
NOTE: Values in bold indicate reduction in standardized differences 
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Appendix 2.4 Characteristics of Renal Cell Carcinoma and non-cancer patients before and 
after propensity score matching – late phase 
Characteristic RCC 
(N = 10,408) 
Non-cancer 
(N = 170,061) 
Standardized 
differences 
before 
matching 
RCC 
(matched) 
(N = 821) 
Non-
cancer 
(matched) 
(N = 821) 
Standardize
d differences 
after (1:1) 
matching 
Age at diagnosis  76.9 (7.4) 81.6 (7.9) 0.6184 76.9 (7.4) 76.9 (7.4) 0.0048 
Age categories  
- 65 to 69 (%) 
- 70 to 75  (%) 
- 76 to 80 (%) 
- > than 80 (%) 
 
 19.1 
26.5 
22.6 
31.8 
 
7.9 
16.0 
19.2 
56.9 
 
0.3308 
0.2582 
0.0840 
0.5208 
 
32.2 
34.4 
18.9 
14.5 
 
30.7 
34.4 
19.6 
21.5 
 
0.0216 
0.0137 
0.0176 
0.0157 
Gender (male %) 57.0 38.8 0.3712 56.9 57.3 0.0607 
Race (%) 
- Caucasian 
- Black 
- Others 
 
88.3 
7.7 
4.0 
 
84.7 
7.1 
8.2 
 
0.1064 
0.0224 
0.1765 
 
88.3 
7.7 
4.0 
 
91.0 
6.6 
2.4 
 
0.0880 
0.0426 
0.0897 
CCI 1.4 (1.7) 1.1 (1.5) 0.1933 1.4 (1.7) 1.3 (1.7) 0.0377 
Urban /Rural (%) 
- Big Metro 
- Metro 
- Urban  
- Less urban 
- Rural 
 
47.1 
29.3 
7.5 
13.2 
2.8 
 
49.9 
31.4 
6.8 
9.8 
2.2 
 
0.0546 
0.0458 
0.0301 
0.1086 
0.0382 
 
47.1 
29.2 
7.6 
13.3 
2.8 
 
48.2 
28.4 
8.2 
11.7 
3.5 
 
0.0219 
0.0188 
0.0226 
0.0479 
0.0417 
Registry (%) 
- S. Francisco 
- Connecticut 
- Detroit 
- Hawaii 
- Iowa 
- N Mexico 
- Seattle 
- Utah 
- Atlanta 
- San Jose 
- Los Angeles 
- Greater Cali 
- Kentucky 
- Louisiana 
- New Jersey 
- Georgia 
 
2.6 
3.8 
4.5 
1.1 
8.3 
2.6 
4.9 
2.8 
2.9 
1.3 
8.0 
20.1 
9.0 
7.8 
11.9 
8.3 
 
3.3 
5.6 
7.1 
1.1 
6.2 
2.8 
5.1 
2.2 
2.8 
2.1 
6.8 
18.4 
7.2 
6.4 
14.2 
8.8 
 
0.0427 
0.0858 
0.1104 
0.0031 
0.0779 
0.0151 
0.0098 
0.0363 
0.0056 
0.0561 
0.0482 
0.0523 
0.0644 
0.0523 
0.0679 
0.0180 
 
2.6 
3.8 
4.5 
1.1 
8.3 
2.6 
4.9 
2.8 
2.9 
1.3 
8.0 
20.3 
9.0 
7.8 
11.9 
8.3 
 
1.7 
3.5 
6.6 
1.5 
6.5 
1.7 
5.1 
4.0 
2.9 
1.3 
6.2 
19.5 
10.7 
8.2 
13.3 
7.3 
 
0.0590 
0.0129 
0.0906 
0.0325 
0.0699 
0.0590 
0.0112 
0.0671 
0.0000 
0.0000 
0.0666 
0.0214 
0.0572 
0.0134 
0.0403 
0.0363 
NOTE: Values in bold indicate reduction in standardized differences 
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Appendix 2.5 Distribution of propensity scores before and after matching by phases 
A. Initial Phase  
Before Match: 
 
After Match: 
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B. Continuing Phase 
Before Match:  
 
After Match: 
 
 
 
43 
 
C. Late Phase 
Before Match 
 
After Match 
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Appendix 2.6. Medical Consumer Price Index values for 2013 and 2015 
Cost category Category used from 
CPI report 
CPI in 2013 CPI in 2015 Multiplication 
factor 
Hospital and ED Inpatient hospital 259.724 303.260 1.168 
Outpatient Outpatient hospital 601.670 672.374 1.118 
Carrier  Professional services  349.468 371.546 1.063 
SNF Nursing home and 
adult day services 
194.472 213.676 1.099 
Prescription 
drugs 
Prescription drugs 442.580 502.510 1.135 
DME Durable medical 
equipment (medical 
supplies and 
equipment) 
101.022 99.272 0.983 
Home health Home health 115.117 120.550 1.047 
Hospice care  No specific category 
(use medical care 
which is average of 
all services) 
425.134 463.675 1.091 
 
Source: Consumer Price Index for all Urban Consumers (CPI-U): U.S. city average, detailed expenditure 
categories 2013 (January 2014 report) and 2015 (December 2015 report) 
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Chapter 3 
Study 2: Utilization of Targeted Therapy and Cytoreductive Nephrectomy among Older 
Adults with Metastatic Renal Cell Carcinoma: Analysis of Survival and Healthcare Costs 
 
ABSTRACT 
Objectives  
Since 2005, targeted therapies have become a standard of care for metastatic renal cell 
carcinoma (mRCC). However, previous studies suggest that 25%-40% of mRCC patients do not 
receive targeted therapies. Furthermore, due to availability of several targeted therapies, there is 
uncertainty about the role of cytoreductive nephrectomy (CN) in the treatment of mRCC. The 
specific aims of this study were 1) to examine the prevalence and predictors of targeted therapy 
and CN use among older mRCC patients 2) to compare the survival and 3) to compare healthcare 
costs among older patients who received targeted therapy alone versus CN + targeted therapy. 
Methods 
This study analyzed the 2007-2014 Surveillance Epidemiology and End Result (SEER)-
Medicare database. Patients newly diagnosed with primary mRCC at the age of 65 or more, who 
also had continuous enrollment in Medicare Parts A, B and Prescription Drug Plans (PartD) were 
included. First, we assessed the predictors of receiving either CN or targeted therapy (any active 
treatment). A multivariable logistic regression assessed the odds for receiving active treatment 
versus no active treatment. Second, we assessed predictors of receiving a CN + targeted therapy. 
A multinomial logistic regression assessed the odds for receiving CN + targeted therapy and CN 
alone versus targeted therapy alone. Third, we compared overall survival (OS), disease-specific 
survival (DSS) and total healthcare costs (THC) between targeted therapy alone and CN + targeted 
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therapy groups. A propensity score based inverse probability of treatment weighting (IPTW) 
method was used to balance the two treatment groups. A Cox proportional hazard model assessed 
the risk for death and a generalized linear model compared the healthcare costs between the groups. 
All costs were inflated to 2016 U.S Dollars. 
Results 
Of 1,263 mRCC patients 672 (53%) received active treatment. Patients diagnosed at age > 
80 years, with NCI comorbidity index scores ≥ 3, and with unknown tumor grade and metastases 
to liver or brain were less likely to receive active treatment. Patients who were married, diagnosed 
from 2010-2013 and with higher tumor involvement were more likely to receive active treatment. 
Of patients receiving active treatment, 360 (54%) received targeted therapy alone, 201 (30%) 
received CN + targeted therapy, and 111 (17%) received CN alone. Patients who had higher lymph 
node involvement, metastasis to bone or liver, lived in North Central or West regions were 
significantly less likely to receive CN + targeted therapy compared to targeted therapy alone. 
Living in urban areas, higher tumor involvement, and poorly differentiated tumor grade increased 
the odds for receiving CN + targeted therapy compared to targeted therapy alone. The median OS 
from the adjusted survival curves was significantly higher (p <0.0001) for CN + targeted therapy 
group (15 months) than the targeted therapy alone group (10 months). CN + targeted therapy group 
had 0.63 times the risk of death (HR = 0.63) compared to the targeted therapy alone group. The 
adjusted total healthcare cost per month was $17,159 for CN + targeted therapy group and $18,120 
for the targeted therapy alone group (p = 0.4389). Sensitivity analysis suggested that total 
healthcare cost tended to be higher for the targeted therapy alone group. 
Conclusions 
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About one-half of older mRCC patients on Medicare did not receive either CN or targeted 
therapy. One-third of patients receiving targeted therapy also underwent CN. Use of CN among 
targeted therapy users was associated with a higher median overall survival and disease-specific 
survival and similar monthly total healthcare cost over a lifetime. Among clinically appropriate 
mRCC patients, CN could play an important role in the targeted therapy era.  
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BACKGROUND 
Renal cell carcinoma (RCC) is the most common type of kidney cancer. About 9 out of 10 
kidney cancers are RCC. The American Cancer Society (ACS) estimated that in 2017, 
approximately 63,990 new kidney cancer cases would be diagnosed and 14,440 people would die 
from this disease.1 The median age of RCC diagnosis is 64 years and men are at two times higher 
risk than women to be diagnosed with RCC. About 15%-40% of RCC patients are diagnosed at 
the metastatic stage and over 30% of those diagnosed at early stages eventually progress to the 
metastatic stage.2, 3  
Before 2005 (cytokine era), systemic therapies for mRCC included cytokine therapy with 
high dose interleukin-2 and interferon-alpha. However, both drugs were associated with low tumor 
response rate, high toxicity, and improvement of less than 6 to12 months in overall survival (OS).4, 
5 Since 2005, the US Food and Drug Administration (FDA) approved several targeted therapies to 
treat mRCC.  These have demonstrated a significant improvement in survival outcomes compared 
to cytokine therapies.6-10 These therapies included the tyrosine kinase inhibitors (TKI) sorafenib, 
sunitinib, pazopanib, axitinib, and cabozantinib; the mammalian target of rapamycin inhibitors 
(mTORi) everolimus and temsirolimus; the anti-vascular endothelial growth factor (VEGF) 
monoclonal antibody bevacizumab and programmed death (PD)-1 check-point inhibitor, 
nivolumab.  
  Currently, cytoreductive nephrectomy (CN) is considered standard prior to systemic 
therapy in appropriate patients with mRCC. The combined use of CN and cytokine therapy 
(referred as CN + targeted therapy henceforth) was well established in the cytokine era. 
Prospective studies conducted during the cytokine era found that mRCC patients who underwent 
CN followed by cytokine therapy had 6 months of higher median survival compared to patients 
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that received cytokine therapy alone. 11-13 However, some studies reported that with the approval 
of targeted therapies since 2005, utilization of CN among mRCC patients has decreased.14, 15 This 
could be due to lack of randomized controlled trials demonstrating the efficacy of the CN + 
targeted therapy. However, retrospective studies published in the last 4-5 years suggested that CN 
+ targeted therapy resulted in a significantly higher OS compared to patients on targeted therapy 
alone.16-18 Nevertheless, the appropriate sequence of therapy remains to be determined.  
Several studies have been conducted among patients who initiated targeted therapies. 
However, little is known about the prevalence and predictors of targeted therapy used alone or in 
combination with CN among older patients that have reached the metastatic stage at the time of 
incident RCC diagnosis. Previous studies conducted among younger populations suggested that 
about 25-40% of mRCC patients did not receive targeted therapy.19, 20 This percentage could be 
much higher among older adults due to the presence of comorbid conditions and frailty. These 
factors could also affect survival outcomes among older patients. Further, none of the studies 
compared healthcare cost between patients receiving targeted therapy alone versus CN + targeted 
therapy. Medicare is the single largest payer for RCC patients, covering about 46% of all RCC 
patients.1, 21 Targeted therapies cost from US $6,000 to $15,000 per month.22 In addition, CN and 
post-surgical care may increase the overall healthcare cost among patients that received CN + 
targeted therapy. However, patients undergoing CN may incur lower healthcare cost due to having 
a several month gaps in targeted therapy treatment after surgery.  
The first aim of this study was to examine the prevalence and predictors of targeted therapy 
and CN use among older adults with mRCC. The study also described characteristics of patients 
that used CN alone, targeted therapy alone and patients that did not receive either CN or targeted 
therapy (referred to as any active treatment henceforth). The second aim of the study was to 
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compare OS and disease-specific survival (DSS) among patients that received targeted therapy 
alone versus CN + targeted therapy. The study hypothesized that patients that used CN + targeted 
therapy compared to targeted therapy alone would have longer OS and DSS. The third aim of the 
study was to compare healthcare cost between patients that received targeted therapy alone versus 
CN + targeted therapy. We hypothesized that patients that received CN + targeted therapy would 
incur higher healthcare cost than targeted therapy alone. 
METHODS 
Data Source23 
SEER-Medicare 
The Surveillance Epidemiology and End Result (SEER) program, initiated by the National 
Cancer Institute (NCI), collects information on cancer statistics in an effort to reduce the cancer 
burden among the U.S population.23 The information collected by this population-based cancer 
registry includes demographics, incident cancer diagnosis, cause of death, cancer stage, tumor 
characteristics, and surgery and radiation therapy provided during the first course of treatment. As 
of 2017, SEER registries covered 28% of the U.S population.24 Medicare data provides 
information on hospital (Part A), outpatient (Part B) and prescription drug (Part D) claims for 
Medicare beneficiaries. SEER-Medicare links SEER and Medicare data and is an excellent source 
to conduct population-based health services research on cancer patients in the U.S.   
We used 2007-2014 SEER-Medicare data. The Patient Entitlement and Diagnosis 
Summary File was used to obtain demographics and cancer diagnosis-related information. 
Resource use and cost-related information were obtained from Medicare Provider Analysis and 
Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies (HHA), 
hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used to obtain 
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inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on hospice 
care utilization. The carrier file provided information on non-institutional physician-provided 
services whereas the outpatient file provided information on institutional physician-provided 
services. The PDE file provided data related to prescription medication use (Medicare Part D). 
DME files provided data on the use of durable medical equipment while HHA files were used to 
get information on services provided in patients’ homes. 
Study Design and Sample Selection 
This was a retrospective cohort study. The study first identified patients with diagnosis of 
RCC using the International Classification of Diseases for Oncology, 3rd edition code C649 and 
relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318'). The criteria developed by the 
American Joint Committee on Cancer (AJCC) - 6th edition, was used to identify Stage-IV patients. 
Further, we limited our sample to stage-IV patients with confirmed distant metastasis (M1 status). 
We excluded patients aged < 65 years, diagnosed with another cancer at the time of RCC diagnosis, 
diagnosed on autopsy, with cancer reported by death certificate, or enrolled in health maintenance 
organization (HMO) plans. Figure 1 depicts the sample selection process in detail. Baseline 
characteristics were identified from the year prior to mRCC diagnosis.  
For OS we followed patients from diagnosis until death or until the end of December 2015. 
For DSS, the study period ended on December 31, 2014 because information on RCC-specific 
death was only available until the end of 2014.  For cost comparisons, we assessed lifetime cost 
defined as costs incurred from the first use of CN or targeted therapy (index date) until death. 
Approximately 86% of the sample had a complete follow-up. We excluded patients that did not 
have a complete follow-up from the cost analysis.  
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Figure 3.1 Sample selection process for this study. 
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Study Measures 
 The study first compared predictors of any active treatment (CN or targeted therapy) versus 
no active treatment. Then, among patients that received active treatment, we assessed predictors 
of CN alone and CN + targeted therapy compared to targeted therapy alone as a reference group. 
Comparisons for survival and costs were conducted between targeted therapy alone and CN + 
targeted therapy groups. Patients that received CN alone or did not receive active treatment were 
excluded from the survival and cost comparisons.  
Targeted therapy / Cytoreductive Nephrectomy  
Oral targeted therapies were identified using generic names and National Drug Codes 
(NDCs) from Medicare Part D while injectable-targeted therapies were identified using healthcare 
procedural codes (HCPC) from Medicare Part B data. Information related to partial or radical 
nephrectomy was obtained from a combination of SEER registry codes, the Current Procedural 
Terminology (CPT) codes from outpatient and carrier files, and ICD9- CM procedure codes from 
inpatient hospital files. The date of first targeted therapy or CN use after mRCC diagnosis was 
considered as the index date. The codes used to identify targeted therapies and CN can be found 
in the Appendix.  
Overall survival /disease-specific survival 
The study defined overall survival as the time in months from the date of diagnosis until 
the date of death or until the end of 2015. Both OS and DSS were calculated. Cause of death 
information from registry data (PEDSF file) was used to identify RCC specific death to calculate 
DSS. Patients that were alive beyond the end of December 2014 were censored.  
Healthcare costs 
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 Costs were the amounts reimbursed by Medicare for each claim related to health services 
utilized by mRCC patients from index date until death. Costs were reported as monthly costs. Total 
healthcare cost was further categorized into prescription drug cost and medical cost. 
Other variables  
 These variables included patient’s sociodemographics, tumor characteristics, site of 
metastasis, histology, claims-based performance status and NCI comorbidity index score. 
Information on these variables was obtained in the year prior to mRCC diagnosis.  
Statistical Analysis 
The study first compared characteristics across treatment modalities using Chi-square test 
for categorical variables and ANOVA for continuous variables. Multivariable (binary) logistic 
regression assessed predictors of active treatment. Among patients who received active treatment, 
multinomial logistic regression was used to assess predictors of CN + targeted therapy and CN 
alone compared to targeted therapy alone. The Andersen Behavior Model (ABM) was used to 
guide the selection of variables (see Figure 2). As per the ABM, factors associated with choice of 
treatment can be characterized into ‘predisposing’ (e.g. age, sex, race), ‘enabling’ (e.g., education 
and income measured at the zip code level), and ‘need’ (e.g. tumor characteristics, histology, NCI 
comorbidity score) factors.25, 26  
A Kaplan Meier curve and log-rank test compared the unadjusted median OS and DSS for 
targeted therapy alone versus CN + targeted therapy groups. To reduce selection bias, we 
calculated propensity score-based inverse probability of treatment weights (IPTW). In the first 
step, we calculated the propensity (probability) of a patient receiving CN + targeted therapy versus 
targeted therapy alone. In the second step, individuals were weighted by the inverse probability of 
receiving the treatment that they actually received. To reduce the bias resulting from extreme 
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weights or propensity scores, stabilized weights were calculated using a technique described by 
Robins et al (2000) and Austin et al. (2009).27, 28 Stabilized weights were then used in a Cox 
proportional hazard model to calculate the risk of death between the two groups. Survival 
probabilities from the Cox proportional hazard model were used to describe adjusted survival 
curves and median survival for both the groups. 
 Similar to survival outcomes, costs were compared using stabilized IPTWs. Due to the 
skewed nature of cost data, generalized linear models (GLMs) with log link and gamma 
distribution was chosen based on results from Modified Park tests, Pearson correlation tests, 
Pregibon link tests, and modified Hosmer and Lemeshow tests. All costs were inflated to 2016 
USD using the Consumer Price Index for medical care services and medical care commodities.29 
All statistical analyses were conducted at an alpha level of 0.05 using SAS v.9.4 (SAS Institute 
Inc., Cary, NC), and STATA (version 13.0, StataCorp, College Station, TX).   
Additional Analyses 
Some mRCC patients may receive delayed treatment or may not require immediate 
treatment with CN or targeted therapy after being diagnosed with mRCC. This may affect the 
comparison of OS and DSS in the study because survival was measured from the date of diagnosis 
and not from the date of treatment initiation. To understand the effect of the definition of the 
follow-up period, we measured survival as the time from treatment initiation until death or until 
the end of the study period. In addition, we used multivariable regression methods instead of 
propensity score-based IPTW to compare survival outcomes and healthcare costs between patients 
who received targeted therapy alone and CN + targeted therapy. 
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Figure 3.2 Conceptual framework adapted from the Anderson Behavioral Model to predict 
the choice of treatment. 
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RESULTS  
Prevalence of Treatment Modalities 
The final study sample included 1,263 patients. Of these, 360 (29%) patients received 
targeted therapy alone, 201 (16%) received CN+ targeted therapy, 111 (9%) patients received CN 
alone and 591 (47%) patients did not receive CN or targeted therapy. Characteristics of patients 
across treatment modalities are presented in Table 3.1 
 
Predictors of receiving CN or targeted therapy versus none 
 
 Multivariable binary logistic regression analysis found that patients who were aged > 80 
years at the time of diagnosis, had NCI comorbidity score of 3 or more, had unknown tumor grade, 
had liver or brain metastasis, and used home health service before diagnosis were significantly (p 
<0.05) less likely to receive CN or targeted therapy. Patients who were married, were diagnosed 
between 2010-2013, and had higher tumor involvement and a higher number of ED visits before 
diagnosis were significantly (p <0.05) more likely to receive CN or targeted therapy. Gender, race, 
SEER region, urban/rural status, tumor size, the extent of lymph node involvement, lung or bone 
metastasis, baseline physician visits or DME use were not significant predictors of receiving CN 
or/targeted therapy (Table 3.2). 
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Table 3.1 Characteristics of mRCC patients by treatment group in study 2 
Characteristic Targeted 
therapy alone 
(n =  360) 
n, % 
CN alone  
 
(n = 111) 
n, % 
CN + targeted 
therapy 
(n= 201) 
n, % 
None  
 
(n = 591) 
n, % 
Age at diagnosis (years) +  
- 65-69 
- 70-75 
- 76-80 
- More than 80 
  
93 (26) 
121 (34) 
89 (25) 
57 (16) 
  
30 (27) 
34 (31) 
34 (31) 
13 (12) 
 
77 (38) 
69 (34) 
44 (22) 
11 (6) 
 
93 (16) 
122 (21) 
130 (22) 
246 (42) 
Sex + 
- Male 
- Female 
  
209 (58) 
151 (42) 
  
60 (54) 
51 (46) 
 
127 (63) 
74 (37) 
 
294 (50) 
297 (50) 
Race/Ethnicity + 
- White 
- Black /others 
  
304 (84) 
56 (16) 
  
>95 (>89) 
<11 (<10) 
 
178 (89) 
23 (11) 
 
500 (85) 
91 (15) 
Marital status + 
- Married 
- Single/Divorced/Separated 
  
186 (52) 
174 (48) 
  
65 (59) 
46 (41) 
 
130 (65) 
71 (35) 
 
229 (39) 
362 (61) 
Zip code- college educated + 
- 0 to 15% 
- 16-20% 
- 21-30% 
- 31% and above 
 
105 (29) 
66 (18) 
75 (21) 
114 (32) 
 
30 (27) 
23 (21) 
27 (24) 
31 (28) 
 
42 (21) 
28 (14) 
46 (23) 
85 (42) 
 
189 (32) 
100 (17) 
131 (22) 
171 (29) 
Zip code level median household 
income (USD) + 
- < 40k 
- 40k - 50 k  
- 51k - 70k 
- > 70 k 
  
  
90 (25) 
85 (24) 
98 (27) 
87 (24) 
 
 
20 (18) 
30 (27) 
35 (32) 
26 (23) 
 
 
34 (17) 
38 (19) 
65 (32) 
64 (32) 
 
 
157 (26) 
147 (25) 
160 (27) 
127 (22) 
Urban/Rural Status  
- Big Metro 
- Metro /Urban 
- Less urban / Rural  
 
62 (17) 
158 (44) 
140 (39) 
  
18 (16)  
51 (46) 
42 (38) 
 
19 (10) 
104 (52) 
78 (39) 
 
 87 (15) 
282 (48) 
222 (38) 
SEER region  
- Northeast 
- South 
- North Central  
- West  
 
55 (15) 
94 (26) 
47 (13) 
164 (46) 
 
24 (22) 
28 (25) 
16 (14) 
43 (39) 
 
38 (19) 
60 (30) 
20 (10) 
83 (41) 
 
101 (17) 
167 (28) 
85 (14) 
 238 (40) 
Year of diagnosis + 
 - 2007 to 2009 
 - 2010 to 2013 
 
125 (35) 
235 (65) 
 
47 (42) 
64 (58) 
 
64 (40) 
100 (60) 
 
272 (46) 
319 (54) 
NCI comorbidity index score + 
   - 0  
   - 1 
   - 2 
   - 3 or more  
 
136 (38) 
106 (29) 
43 (12) 
75 (21) 
 
55 (50) 
26 (23) 
18 (16) 
12 (11) 
 
89 (45) 
67 (33) 
22 (11) 
23 (11)  
 
196 (33) 
138 (23) 
86 (15) 
171 (29) 
+ Statistically significant differences based on chi-square test / ANOVA, p < 0.05 
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Table 3.1 Continued  
Characteristic Targeted 
therapy alone 
(n =  360) 
n, % 
CN alone  
 
(n = 111) 
n, % 
CN + targeted 
therapy 
(n = 201) 
n, % 
None  
 
(n = 591) 
n, % 
NCI comorbidity index score + 
(mean, standard deviation) 
 
1.3 (1.5) 
  
0.9 (1.2) 
 
1.0 (1.2) 
 
1.8 (2.0) 
Tumor size + 
- Unknown / < 5 cm 
- 5 to 7.9 cm 
- ≥ 8 cm 
 
66 (23) 
88 (31) 
134 (47) 
 
21 (19) 
34 (30) 
55 (50) 
 
22 (12) 
56 (29) 
114 (59) 
 
129 (29) 
149 (33) 
173 (38) 
Tumor grade + 
- Well/ moderate 
- Poor / undifferentiated  
- Unknown 
 
42 (11) 
25 (7) 
293 (82) 
 
23 (21) 
66 (60) 
22 (20) 
 
44 (21) 
111 (59) 
46 (20) 
 
21 (4) 
42 (7) 
528 (89) 
Tumor extent (T) - TNM + 
  -  T0 / T1/ unknown 
  -  T2  
  -  T3  
  -  T4 
 
186 (52) 
59 (16) 
79 (22) 
36 (10) 
 
23 (21) 
14 (13) 
61 (55) 
13 (12) 
 
31 (15) 
32 (16) 
122 (61) 
16 (8) 
 
363 (61) 
78 (13) 
97 (16) 
53 (9) 
Lymph Node (N) - TNM + 
 - N0 /NX 
 - N1 /N2  
 
250 (69) 
110 (31) 
 
88 (79) 
23 (21) 
 
153 (76) 
48 (24) 
 
458 (77) 
133 (23) 
Histology  
- Clear cell 
- Non-clear cell  
 
333 (93) 
27 (7) 
 
94 (85) 
17 (15) 
 
174 (87) 
27 (13) 
 
547 (93) 
44 (7) 
Site of metastasis 
- Bone (yes) 
- Lung (yes) 
- Liver (yes)  
- Brain (yes) 
 
177 (49) 
204 (57) 
74 (21) 
51 (14) 
 
26 (23) 
54 (49) 
22 (16) 
13 (12) 
 
57 (28) 
113 (56) 
18 (10) 
17 (9) 
 
253 (43) 
319 (54) 
145 (25) 
96 (16) 
Performance status indicators 
Average number of services 
(mean, standard deviation) 
 - ED visits + 
 - hospital days+ 
 - SNF days+ 
 - physician claims + 
 - home health claims+ 
 
DME use (%) + 
Assisting devices (%) + 
 
 
 
4.0 (3.3) 
0.5 (1.8) 
1.0 (8.5) 
31.0 (24.9) 
0.2 (0.7) 
 
140 (39) 
76 (21)  
 
 
 
4.0 (3.7) 
1.7 (9.2) 
2.5 (16.5) 
29.9 (25.4) 
0.1 (0.5) 
 
39 (35) 
14 (13) 
 
 
 
4.2 (3.7) 
0.7 (2.4) 
0 (0) 
30.4 (25.3) 
0.0 (0.3) 
 
59 (29) 
20 (10) 
 
 
 
2.9 (2.7) 
1.6 (6.4) 
4.2 (17.0) 
36.2 (35.3) 
0.4 (1.0) 
 
249 (42) 
130 (22) 
+ Statistically significant differences based on chi-square test / ANOVA, p < 0.05 
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), 
and the presence of metastasis (M). 
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Table 3.2 Multivariable logistic regression assessing predictors of CN or targeted therapy 
(any treatment) versus no treatment among mRCC patients.    
 
Characteristic Odds Ratio 
(CN/ targeted therapy vs None) 
95% CI p-value 
Age at diagnosis (years)  
- 65-69 
- 70-75 
- 76-80 
- More than 80 
 
Reference 
0.98 
0.78 
0.25  
 
 
0.66 - 1.46 
0.52 - 1.18 
0.16 - 0.38 
 
 
<0.0001 
Sex  
- Female 
- Male 
 
Reference 
1.04 
 
 
0.77 - 1.41 
 
0.8079 
Race/Ethnicity  
- Black /others 
- White 
 
Reference 
0.96 
 
 
0.64 - 1.43 
 
 
0.8211 
Marital status  
- Single/Divorced/Separated 
- Married 
 
Reference 
1.80  
 
 
1.33 - 2.42 
 
 
0.0001 
Zip code- college educated  
- 0 to 15% 
- 16-20% 
- 21-30% 
- 31% and above 
 
Reference 
1.61 
1.57 
1.48 
 
 
1.02 - 2.51 
0.99 - 2.47 
0.88 - 2.49 
 
 
0.0390 
0.0532               
0.1385                             
Zip code level median household 
income (USD)  
- < 40k 
- 40k - 50 k  
- 51k - 70k 
- > 70 k 
 
 
Reference 
0.78 
0.88 
1.01 
 
 
 
0.50 - 1.21 
0.55 - 1.41 
0.56 - 1.84 
 
 
 
0.2611 
0.5938 
0.9645 
Urban/Rural Status  
- Less urban / Rural  
- Metro /Urban 
- Big Metro 
 
Reference 
0.81 
0.80 
 
 
0.49 - 1.33 
0.50 - 1.27 
 
 
0.3974 
0.3377 
SEER region  
- Northeast 
- South 
- North Central  
- West  
 
Reference 
1.00 
0.74 
1.00 
 
 
0.62 - 1.64 
0.43 - 1.29 
0.67 - 1.51 
 
 
0.9720 
0.2852 
0.9728 
Year of diagnosis + 
 - 2007 to 2009 
 - 2010 to 2013 
 
Reference 
1.66 
 
 
1.24 - 2.24 
 
 
0.0008 
NCI comorbidity index score + 
   - 0  
   - 1 
   - 2 
   - 3 or more  
 
Reference 
1.11 
1.30 
0.55 
 
 
0.77 - 1.61 
0.50 - 1.24 
0.34 - 0.88 
 
 
0.5666 
0.2971 
0.0124 
Note: p-value < 0.05 indicates statistically significant association 
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Table 3.2 (continued) 
Characteristic Odds Ratio 
(CN / targeted therapy 
vs None) 
95% CI p-value 
Tumor size  
- Unknown / < 5 cm 
- 5 to 7.9 cm 
  - ≥ 8 cm 
 
Reference 
1.12 
1.30 
 
 
0.77 - 1.61 
0.86 - 1.96  
 
 
0.5619 
0.2078 
Tumor grade  
- Well/ moderate 
- Poor / undifferentiated  
  - Unknown 
 
Reference 
0.66 
0.15 
 
 
0.34 - 1.28 
0.08 - 0.26 
 
 
0.2134 
<0.0001 
Tumor extent (T) - TNM + 
  -  T0 / T1/ unknown 
  -  T2  
  -  T3  
  -  T4 
 
Reference 
1.37 
2.30 
1.56 
 
 
0.84 - 2.21 
1.55 - 3.40 
0.93 - 2.62 
 
 
0.2043 
<0.0001 
0.0928 
Lymph Node (N) - TNM  
 - N0 /NX 
 - N1 /N2  
 
Reference 
0.95  
 
 
0.68 - 1.31 
 
 
0.7464 
Histology  
- Non-clear cell 
  - Clear cell 
 
Reference 
1.06 
 
 
0.64 - 1.73 
 
 
0.8288 
Bone metastasis 
 - Absent 
 - Present  
 
Reference 
1.00 
 
 
0.75 - 1.36 
 
 
0.9641 
Lung metastasis  
  - Absent  
  - Present  
 
Reference 
0.76 
 
 
0.57 - 1.02 
 
 
0.0673 
Liver metastasis  
  - Absent  
  - Present 
 
Reference 
0.59 
 
 
0.42 - 0.83 
 
 
0.0023 
Brain metastasis 
 - Absent  
 - Present 
 
Reference 
0.48 
 
 
0.32 - 0.72 
 
 
0.0004 
Performance status indicators 
Average number of services 
 - ED visits  
 - hospital days 
 - SNF days 
 - physician claims 
 - home health claims 
DME use (Yes vs No) 
Assisting devices (Yes vs No) 
 
 
1.24 
0.97 
0.99 
1.00 
0.75 
0.96 
1.10  
 
 
1.17 - 1.31 
0.94 - 0.99 
0.98 - 1.00 
0.99 - 1.01 
0.60 - 0.93 
0.65 - 1.42 
0.70 - 1.73 
 
 
<0.0001 
0.0273 
0.2474 
0.1889 
0.0102 
0.8436 
0.6881 
 
Note: p-value < 0.05 indicates statistically significant association 
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the 
presence of metastasis (M). 
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Predictors of receiving CN+ targeted therapy versus targeted therapy alone. 
Multinomial logistic regression analysis found that patients who were > 80 years old at the 
time of diagnosis, lived in North Central or West regions, had higher lymph node involvement, 
had bone or liver metastasis, had unknown tumor grade were significantly (p <0.05) less likely to 
receive CN + targeted therapy compared to targeted therapy alone. Patients who lived in urban 
areas, had higher extent of tumor involvement, had poorly differentiated tumor grade, had a higher 
number of ED visits before cancer diagnosis were significantly (p <0.05) more likely to receive 
CN+ targeted therapy versus targeted therapy alone.  
Predictors of receiving CN alone versus targeted therapy alone. 
Multinomial logistic regression analysis found that patients who had NCI comorbidity 
score of 3 or more, lived in South, North Central or West regions, had higher lymph node 
involvement, had bone or lung metastasis, had unknown tumor grade were significantly (p <0.05) 
less likely to receive CN alone compared to targeted therapy alone. Patients who had greater extent 
of tumor involvement, poorly differentiated tumor grade, and more hospital stays before cancer 
diagnosis were significantly (p <0.05) more likely to receive CN alone compared to targeted 
therapy alone. (Table 3.2)  
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Table 3.3 Multinomial logistic regression assessing predictors of CN + targeted therapy and 
CN alone versus targeted therapy alone among older mRCC patients.  
 
Characteristic CN alone (N = 111)  
vs targeted therapy alone  
(N = 360) 
CN + targeted therapy (N = 201) 
vs targeted therapy alone  
(n = 360) 
 Odds Ratio 95% CI Odds Ratio 95% CI 
Age at diagnosis (years) 
- 65-69 
- 70-75 
- 76-80 
- More than 80 
 
Reference 
0.94 
1.24 
0.74        
 
 
0.45 - 1.96 
0.57 - 2.68 
0.27 - 2.02                   
 
Reference 
0.73 
0.60 
0.24 
 
 
0.40 - 1.35 
0.31 - 1.17 
0.09 - 0.61 
Sex  
- Female 
- Male 
 
Reference 
0.92 
 
 
0.49 - 1.74 
 
Reference 
1.26 
 
 
0.72 - 2.21 
Race/Ethnicity  
- Black /others 
- White 
 
Reference 
1.89 
 
 
0.74 - 4.80 
 
Reference 
1.39 
 
 
0.64 - 3.04 
Marital status  
- Single/Divorced/Separated 
- Married 
 
Reference 
1.12 
 
 
0.59 - 2.11 
 
Reference 
1.31 
 
 
0.76 - 2.27 
Zip code- college educated  
- 0 to 15% 
- 16-20% 
- 21-30% 
- 31% and above 
 
Reference 
0.81 
1.06 
0.48 
 
 
0.33 - 1.98 
0.43 - 2.65 
0.16 - 1.42 
 
Reference 
0.95 
1.53 
1.53 
 
 
0.41 - 2.17 
0.67 - 3.49 
0.60 - 3.87 
Zip code level median 
household income (USD)  
- < 40k 
- 40k - 50 k  
- 51k - 70k 
- > 70 k 
 
 
Reference 
1.51 
1.81 
1.49 
 
 
 
0.59 - 3.85 
0.66 - 4.92 
0.41 - 5.47 
 
 
Reference 
0.88 
1.13 
0.71  
 
 
 
0.39 - 2.02 
0.47 - 2.70 
0.24 - 2.12 
Urban/Rural Status  
- Less urban / Rural  
- Metro /Urban 
- Big Metro 
 
Reference 
1.41 
0.99 
 
 
0.53 - 3.76 
0.40 - 2.41 
 
Reference 
3.62 
1.94 
 
 
1.45 - 9.06 
0.84 - 4.48 
SEER region  
- Northeast 
- South 
- North Central  
- West  
 
Reference 
0.37 
0.19 
0.24 
 
 
0.14 - 0.98 
0.06 - 0.61 
0.10 - 0.54 
 
Reference 
0.98 
0.30 
0.41 
 
 
0.43 - 2.24 
0.10 - 0.86 
0.21 - 0.84 
Year of diagnosis  
 - 2007 to 2009 
 - 2010 to 2013 
 
Reference 
1.31 
 
 
0.70 - 2.42 
 
Reference 
1.29 
 
 
0.75 - 2.21 
NCI comorbidity index score  
   - 0  
   - 1 
   - 2 
   - 3 or more  
 
Reference 
0.54 
1.10 
0.20  
 
 
0.26 - 1.14 
0.45 - 2.70 
0.07- 0.61                  
 
Reference 
0.99 
0.74 
0.40  
 
 
      0.54 - 1.83  
      0.32 - 1.71 
      0.16 - 1.00                           
Notes: Values in bold indicate a statistically significant association 
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Table 3.3 (continued) 
Characteristic CN alone (N = 111)  
vs targeted therapy alone (N = 360) 
CN + targeted therapy (N = 201) 
vs targeted therapy alone (360) 
 Odds Ratio 95% CI Odds Ratio 95% CI 
Tumor size  
- Unknown / < 5 cm 
- 5 to 7.9 cm 
  - ≥ 8 cm 
 
Reference 
1.42 
1.28  
 
 
0.62 - 3.19 
0.54 - 3.02                    
 
Reference 
1.35 
1.42        
 
 
0.66 - 2.76 
0.67 - 2.99 
Tumor grade  
- Well/ moderate 
- Poor / undifferentiated  
  - Unknown 
 
Reference 
6.36 
0.16    
 
 
2.71 - 14.88 
0.07 - 0.35                    
 
Reference 
4.63 
0.16  
 
 
2.15 - 9.98 
0.08 - 0.30 
Tumor extent (T) - TNM  
  -  T0 / T1/ unknown 
  -  T2  
  -  T3  
  -  T4 
 
Reference 
2.13 
5.56 
2.48   
 
 
0.78 - 5.81 
2.46 - 12.57 
0.82 - 7.55                    
 
Reference 
2.13 
6.17  
1.72  
 
 
0.92 - 4.91 
  3.06 - 12.43 
0.61 -  4.82                                        
Lymph Node (N) - TNM  
 - N0 /NX 
 - N1 /N2  
 
Reference 
0.17  
 
 
0.08 - 0.36                    
 
Reference 
0.26  
 
 
0.14 - 0.49                    
Histology  
- Non-clear cell 
  - Clear cell 
 
Reference 
2.58  
 
 
0.98 - 6.74 
 
Reference 
2.21 
 
 
0.93 - 5.27 
Bone metastasis 
- Absent 
- Present  
 
Reference 
0.30  
 
 
0.16 - 0.56                    
 
Reference 
0.45  
 
 
0.26 - 0.78 
Lung metastasis  
  - Absent  
  - Present  
 
Reference 
0.49  
 
 
0.27 - 0.90                    
 
Reference 
0.77  
 
 
0.46 - 1.31 
Liver metastasis  
 - Absent  
 - Present 
 
Reference 
0.93  
 
 
0.45 - 1.95                    
 
Reference 
0.48  
 
 
0.24 - 0.95 
Brain metastasis 
 - Absent  
 - Present 
 
Reference 
0.97  
 
 
0.39 - 2.42                    
 
Reference 
0.52  
 
 
0.23 - 1.21 
Performance status indicators*  
Average number of services 
 - ED visits  
 - hospital days 
 - physician claims 
 - home health claims 
DME use (Yes vs No) 
Assisting devices (Yes vs No) 
 
 
1.08 
1.14  
1.00         
1.37  
1.27 
0.72  
 
 
0.98 - 1.17 
1.01 - 1.28 
0.98 - 1.01 
0.85 - 2.20 
0.57 - 2.84 
0.26 - 1.97                                        
 
 
1.10  
1.07  
1.00  
0.43  
0.84  
0.70
 
 
1.02 - 1.19 
0.95 - 1.20                    
0.99 - 1.02                    
0.17 - 1.10                    
0.41 - 1.72                    
0.28 - 1.77 
Notes: Values in bold indicate statistically significant association; * SNF use was excluded due to small sample size  
TNM: A staging system based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the 
presence of metastasis (M). 
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Overall Survival and Disease-Specific Survival between CN + Targeted therapy versus 
Targeted therapy Alone. 
 Unadjusted Kaplan Meier analysis found that the median OS for CN+ targeted therapy 
group was significantly higher than for the targeted therapy alone group (21 months vs 10 months, 
p <0.0001).  Similarly, CN + targeted therapy group had significantly higher DSS than the targeted 
therapy alone group (20 months vs 10 months, p <0.0001). Kaplan Meier curves for the OS and 
DSS are displayed in Figure 3.2 
 A Cox proportional hazard model after IPTW found that compared to patients that received 
targeted therapy alone, CN+ targeted therapy group had 0.59 times lower risk for death (HR = 
0.59, 95% CI: 0.56 - 0.62; p <0.0001) due to any reason (OS). Similarly, CN + targeted therapy 
group had 0.63 times lower risk for RCC-related death (DSS) (HR = 0.63, 95%CI: 0.60 - 0.67; p 
<0.0001) compared to CN + targeted therapy group. Additionally, we used survival probabilities 
from the Cox proportional model to describe adjusted survival curves for OS and DSS (Figure 3). 
Adjusted survival curves indicated that the median OS and DSS were 5 months higher for CN+ 
targeted therapy group (15 months) compared to targeted therapy alone (10 months).   
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Figure 3.3 Kaplan Meier Survival curves comparing overall survival and disease-specific 
survival between CN+ targeted therapy and targeted therapy alone groups. 
 
a. Overall survival 
  
b. Disease specific survival  
   
       
 
NOTE: Statistically significant difference for OS and DSS; p-value < .0001 
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Figure 3.4 Adjusted overall survival and disease-specific survival between CN + targeted 
therapy and targeted therapy alone groups. 
 
a) Overall survival  
 
 
b) Disease-specific survival 
 
NOTE: Statistically significant difference for OS and DSS; p-value <0.0001 
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Healthcare Cost between CN + Targeted therapy vs Targeted therapy Alone. 
 
 Unadjusted average (monthly) total healthcare cost, medical cost and prescription drug cost 
are described in Table 3.4 There was no statistically significant difference in the total healthcare 
cost and medical cost between CN + targeted therapy and targeted therapy alone groups. However, 
prescription drug costs were significantly higher (p<0.05) for the targeted therapy alone group 
($5,701) compared to CN + targeted therapy group ($2,692).  
 Generalized linear models using the log link and gamma distribution (after propensity score 
based IPTW) indicated that the total healthcare cost was similar (p = 0.4389) for the targeted 
therapy alone group ($ 18,120) compared to CN + targeted therapy group ($ 17,159). The medical 
cost was significantly higher for CN + targeted therapy group ($ 14,197) compared to targeted 
therapy alone group ($ 10,607); whereas prescription drug cost ($ 7,573) was significantly higher 
for the targeted therapy alone group compared to CN + targeted therapy group ($ 2,962).  
 
Table 3.4 Unadjusted comparison of total healthcare costs, medical costs and prescription 
drug costs between CN+ targeted therapy and Targeted therapy alone groups. 
 CN + targeted therapy (n = 154) Targeted therapy alone (n = 326) 
Monthly Costs Mean (US $) Median (US $) Mean (US $) Median (US $) 
Total healthcare costs 14,005 11,551 17,012 12,596 
Medical costs 10,925 7,784 11,310 7,737 
Prescription drug costs 3,081 2,692 5,701 * 4,751 
* Significantly higher cost (p <0.05) based on Wilcoxon Mann Whitney test  
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Table 3.5. Generalized linear model (including IPTWs) assessing total healthcare costs, 
medical costs and prescription drug costs between CN+ targeted therapy and targeted 
therapy alone groups. 
Average costs per month CN + targeted therapy  
(n = 154) 
Mean (95%CI) 
Targeted therapy alone  
(n = 326) 
Mean (95%CI) 
p-value 
Total healthcare costs 17,159 (15,294 - 19,252)  18,120 (16,791 - 19,554) 0.4389 
Medical costs 14,197 (12,385 - 16,275) 10,607 (9,689 - 11,612) 0.0005 
Prescription drug costs 2,962 (2,482 - 3,535) 7,573 (6,735 - 8,516)  <0.0001 
Note: Covariates were included in the propensity score model to calculate IPTWs. The generalized linear model was 
run after IPTW to get cost estimates.  
 
Additional Analysis  
First, we assessed sociodemographic and clinical predictors of targeted therapy use among 
mRCC patients. Details about the predictors of targeted therapy use are described in Appendix 3.7 
Patients that were younger at the time of diagnosis, married, and diagnosed in the late targeted 
therapy era had higher odds for receiving targeted therapies. As the NCI comorbidity score 
increased the odds for patients receiving targeted therapy decreased. Further, presence of liver or 
brain metastasis, and poor or unknown tumor grade decreased the odds for receiving targeted 
therapies. Odds for receiving targeted therapies also decreased with an increase in the average 
number of hospital stays and home health visits. Second, we assessed the overall survival between 
mRCC patients who received targeted therapies and patients who did not. These results can be 
found in Appendix 3.8. Adjusted survival curves suggested that median OS was 9 months for 
targeted therapy users and 4 months for patients that did not receive targeted therapies. A Cox 
proportional hazard model (after IPTW) found that patients who received targeted therapies had 
0.57 times risk of death compared to patients who did not receive targeted therapy (HR = 0.57, 
95%CI: 0.51 - 0.64, p < 0.0001). 
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Third, for the survival analysis that compared CN + targeted therapy and targeted therapy 
alone groups, we considered survival as the time from treatment initiation (either CN or targeted 
therapy) to death or end of 2014. The adjusted OS and DSS curves and hazard ratios were similar 
to our main analysis where survival was measured as a time from diagnosis. Fourth, instead of 
propensity scoring, we used multivariable Cox proportional hazard models. In the model assessing 
OS, patients from CN + targeted therapy had 0.37 (95% CI: 0.28 - 0.49) times lower risk of death 
compared to targeted therapy alone controlling for all other covariates. The risk of death for CN + 
targeted therapy was much lower in the regression model as compared to propensity score-based 
method, which suggested that our findings based on propensity score-based IPTW method were 
more conservative than the regression approach. Fifth, similar to survival outcomes, for the cost 
analysis, we conducted multivariable regression analysis instead of propensity score-based IPTW. 
Costs from the multivariable GLM indicated higher total healthcare cost for the targeted therapy 
alone group, most of which, was driven by higher prescription drug costs as medical costs were 
similar between the groups.  
 
Discussion 
 This study analyzed SEER-Medicare data to compare survival and healthcare costs among 
mRCC patients diagnosed at age 65 and older, who received CN and targeted therapy versus 
targeted therapy alone. We also assessed the prevalence and predictors of targeted therapy and/or 
CN use in this population. Among newly diagnosed mRCC patients, only 44% received targeted 
therapy and 25% received CN. About 47% did not receive either targeted therapy or CN, which 
are considered as primary treatments for mRCC. Patients who received CN and targeted therapy 
had higher OS and DSS compared to patients who received targeted therapy alone. Average 
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monthly total healthcare costs were similar for patients who received CN and targeted therapy 
versus targeted therapy alone.  
The prevalence of targeted therapy recipients in our study (44%) was much lower than an 
estimate of 60-70% reported by studies conducted among younger populations.19, 20 Similarly, the 
prevalence of any active treatment (53%) in our study was also much lower than the prevalence 
(70%) reported in previous studies. However, it was higher than the estimate from a study 
conducted among older Medicare patients in the cytokine era, in which only 30% patients received 
either CN or cytokine therapy.30 Additionally, patients diagnosed in the later part of targeted 
therapy era (2010-2013) were more likely to receive active treatment. This suggested that a higher 
number of older mRCC patients received active treatment in the targeted therapy era, probably 
because more targeted therapies became available. This trend was consistent with the findings 
from Banegas et al.19  Patients aged ≥ 80 years at the time of diagnosis and who were single/ 
unmarried/ divorced were less likely to receive CN or targeted therapy. These findings were 
consistent with previous studies.19, 30. However, in contrast to Saigal et al.30 we did not find any 
racial/ethnic disparity in our study. Clinical factors - unknown tumor grade, NCI comorbidity 
index score of ≥ 3, presence of liver/ brain metastasis, hospital stays and home health service use 
in the year prior to diagnosis were associated with not receiving active treatment. This suggested 
that patients who had higher comorbidities or poor health status at the time of diagnosis were not 
good candidates to receive active treatment; possibly because the risks associated with active 
treatment might outweigh their benefits.  
Among patients that received active treatment, we assessed predictors of receiving CN + 
targeted therapy compared to patients that received targeted therapy alone. Results from the 
multivariable model indicated that patients with advanced age at the time of cancer diagnosis, 
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comorbidities, metastases to liver/ bone/ brain, and higher lymph node involvement were less 
likely to receive CN + targeted therapy compared to targeted therapy alone. Poor/undifferentiated 
tumor grade or T3 stage was associated with higher odds to receive CN. These findings were 
consistent with findings from Hanna et al.17 In addition, we observed a geographical discrepancy 
in the use of CN such that patients from rural areas (compared to urban) or living in North Central 
and West regions (compared to Northeast region) were less likely to receive CN with or without 
targeted therapy. Future studies could further investigate reasons for geographical disparity for CN 
use among mRCC patients. 
Findings from the adjusted survival analysis suggested that the use of CN among targeted 
therapy users was associated with six additional months of median OS. Unadjusted Kaplan Meier 
analysis suggested an additional OS of 10 months. Results from a Cox proportional hazard model 
after IPTW suggested that patients who used both CN and targeted therapy had a lower risk of 
death compared to patients receiving targeted therapy alone. The results from the propensity score 
based IPTW model were more conservative than the multivariable regression model but had the 
same directionality. Our findings were consistent with the findings from previous retrospective 
studies.16, 17 Heng et al. analyzed IMDC database and found that the risk of death for targeted 
therapy users who received CN was significantly lower (HR = 0.60, 95% CI: 0.52 - 0.69) than 
patients who received targeted therapy alone.16 Similarly, Hanna et al, using the National Cancer 
Data Base (NCDB), found that patients who received both CN and targeted therapy had a lower 
risk of death (HR = 0.49, 95%CI: 0.46 to 0.52) compared to patients on targeted therapy alone.17  
Findings from our and other retrospective studies, however, were not consistent with a 
recently published prospective RCT (CARMENA).31 This non-inferiority RCT compared survival 
outcomes among patients receiving CN followed by sunitinib versus sunitinib alone. The study 
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found that the sunitinib alone group had a higher OS (18.4 months) than patients who received CN 
and sunitinib (13.9 months). The HR of 0.89 (95%CI: 0.71- 1.10) was non-significant suggesting 
that sunitinib alone was not considered inferior to patients who received CN + sunitinib. No 
significant differences were observed for other outcomes such as progression free survival. This is 
the only prospective study that has assessed the role of CN among mRCC patients in the targeted 
therapy era.  
      As prospective studies have better internal validity and minimal selection bias, they are often 
considered as the gold standard and provide a higher level of evidence than retrospective studies. 
As a result, use of CN among mRCC patients may be questioned in the near future. Conflicting 
findings from the CARMENA study compared to retrospective studies may generate uncertainty 
in decision-making, as the risk associated with CN may not outweigh survival benefits among 
mRCC patients.  
It is important to highlight key differences between CARMENA study and our study. The 
CARMENA study included patients that were good candidates for CN and sunitinib and excluded 
patients who had brain metastasis, cardiovascular comorbidities or poor performance status. The 
median age was 62 years. In contrast, in our study, the median age was 73 years. We did not 
exclude patients based on metastasis, comorbidities or performance status. Further, although the 
CARMENA study was randomized there were differences between treatment groups for the extent 
of tumor (T) and lymph node (N) involvement. These differences may affect survival outcomes 
between the treatment groups. In our study, we controlled for these differences using the IPTW 
method. CARMENA study controlled for prognostic risk calculated using MSKCC criteria. 
Although our study did not control for prognostic risk, other retrospective studies whose findings 
were similar to ours did control for baseline risk of prognosis. 
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As a prospective RCT, the CARMENA study certainly had higher internal validity than 
retrospective studies but the stricter inclusion/exclusion criteria may affect the generalizability of 
study findings. A pragmatic trial that has less strict inclusion/exclusion criteria, conducted in the 
U.S, which enrolls older mRCC patients from the real world clinical practice setting, may provide 
a middle ground between RCTs and observational studies. It may also address the issue of 
conflicting findings and provide evidence on the effectiveness of CN in the targeted therapy era.  
No study to our knowledge has compared healthcare costs between mRCC patients who 
received CN+ targeted therapy versus targeted therapy alone. Results from our cost analysis 
suggested that patients receiving CN + targeted therapy had similar total healthcare costs to 
patients receiving targeted therapy alone. However, they had higher medical costs and lower 
prescription costs compared to patients who received targeted therapy alone. Higher medical costs 
could be due to the additional cost of CN and morbidity and post-surgical complications associated 
with CN.32 Lower prescription drug costs for this group could be due to delayed initiation of 
targeted therapy after CN. The average time to receive targeted therapy after CN in our study was 
6 months (median was 2.5 months). Although results from our cost analyses were not consistently 
robust, all suggested that use of CN did not result in higher total healthcare cost; costs were either 
similar or lower than the targeted therapy alone group. 
The results of the study should be interpreted in light of several limitations. First, although 
we used a propensity score based IPTW method to reduce selection bias, we could not control for 
performance status of patients, prognosis, patient and physician preferences or lifestyle factors, all 
of which may affect treatment choice and survival outcomes. SEER-Medicare data does not 
provide information on performance as measured by the Karnofsky Performance Scale or the 
Eastern Cooperative Oncology Group scale.33 However, to reduce the effect of this limitation, we 
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measured claims-based performance status from Medicare claims data as suggested by Salloum et 
al.34  SEER-Medicare also does not provide information on lab values for hemoglobin, calcium, 
neutrophils, and platelets, which are used to assess prognosis using criteria developed by Heng et 
al.35 and the Memorial Sloan-Kettering Cancer Center.36 However, we controlled for tumor 
characteristics such as tumor grade, site of metastasis, histology, the extent of lymph node 
involvement, which are associated with overall survival. Second, registry and administrative 
claims data are subject to miscoding errors, which may affect treatment assignment and outcomes 
assessed in the study. Claims data is used for reimbursement purposes and may not accurately 
reflect patients’ behavior.  For example, prescription claims indicate that the prescription was filled 
at the pharmacy but do not guarantee actual use by patients. Third, SEER only began collecting 
information on metastasis to bone, liver, lung, and brain in 2010. Hence, for patients diagnosed 
before 2010, we used ICD9-CM codes to identify sites of metastasis. However, according to the 
NCI, this information could be underreported in ICD9-CM codes because physicians are not 
required to report site of metastasis to get reimbursed from CMS.37 However, in our study 
population, there was a 90% agreement on the site of metastasis reported by SEER after 2010 and 
claims-based metastasis for patients diagnosed after 2010. Fourth, this study was conducted among 
Medicare patients aged ≥ 65 years at the time of diagnosis and living in SEER areas. Therefore, 
findings from this study may not be generalizable to younger mRCC patients or patients living 
outside of SEER areas. Fifth, SEER collects cancer stage and tumor-related information only at 
the first cancer diagnosis and does not measure disease progression. Therefore, we could not 
include patients diagnosed at earlier stages who may have later progressed to stage-IV.  
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Conclusions 
About one-half of older mRCC patients on Medicare did not receive either CN or targeted 
therapy. One-third of patients receiving targeted therapy also underwent CN. In addition to the 
clinical factors, a geographical disparity exists in the receipt of CN, which may also affect survival 
among patients living in these areas. Our findings, when taken in the context of previously 
published studies, suggest that among clinically appropriate mRCC patients CN plays an important 
role in extending overall survival. Furthermore, use of CN among targeted therapy users is not 
associated with an increase in the lifetime total healthcare costs to Medicare. 
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Appendix for study 2 
Appendix 3.1 Codes used for identifying targeted therapy and cytoreductive nephrectomy 
 Drug name NDC codes (PDE file) HCPCS (Outpatient, 
Carrier files) 
Suntinib 00069055030, 00069055038, 00069077030, 
00069077038, 00069083038, 00069098030, 
00069098038, 54569598200, 54569598300 
-- 
Sorafenib 00026848858, 50419048858 -- 
Pazopanib 00173080409, 00078067066 -- 
Everolimus 00078056651, 00078056661, 00078056751, 
00078056761, 00078059451, 00078059461, 
00078062051, 00078062061, 00078041420, 
00078041520, 00078041720, 0078062851, 
00078062861, 0078062751, 00078062761, 
00078062661, 00078062651, 00078041761, 
00078041561, 00078041461,  
-- 
Axitinib 00069014501, 00069015111 -- 
Bevacizumab 50242006001, 50242006101 J9035, C9257 
Temsirolimus 00008117901, 00008117905      C9239, J9330 
Interferon 
alpha 
-- J9212, J9213, J9214, 
J9215 
Interleukin -- J2355, J9015 
 
Appendix 3.2 Codes for cytoreductive nephrectomy  
Files Codes 
SEER surgery codes 30, 40, 50, 70, 80 
Carrier and outpatient files 
(HCPCS / CPT codes) 
50220, 50225, 50230, 50234, 50236, 50240, 50280, 50290, 
50542, 50543, 50545, 50546, 50548, 50549 
Inpatient hospital file (ICD 
9- CM procedure codes) 
5501, 554, 5551, 5552, 5553, 5554, 5531, 5539, 5540 
 
Appendix 3.3 ICD 9-CM codes for metastasis 
Site of metastasis ICD9-CM codes 
Bone 198.5 
Brain 198.3, 198.4 
Liver 197.7 
Lung 197.0, 197.1, 197.2, 197.3 
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Appendix 3.4 Adjusted survival curves for CN + targeted therapy vs targeted therapy alone 
when survival was measured as a time from treatment initiation until death/end of the study 
period 
a. Overall Survival  
 
b. Disease-specific survival 
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Appendix 3.5 Multivariable Cox proportional hazard model assessing risk of death among 
mRCC patients who received CN + targeted therapy versus targeted therapy alone 
 
 Hazard Ratio (HR) 95%CI for HR p-value 
Overall survival (n = 561)  
Targeted therapy alone Reference --  
CN + targeted therapy  0.37 0.28 - 0.49 <0.0001 
Disease specific survival (n = 499)  
Targeted therapy alone Reference --  
CN + targeted therapy  0.34 0.25 - 0.46 <0.0001 
Note: Covariates included age, gender, race, marital status, zip code level income, zip code level 
education, SEER region, urban rural status, NCI comorbidity index, tumor size, tumor grade, 
tumor extent (T), lymph node extent (N), cell type, era of diagnosis, metastases to liver / 
lung/bone/brain, claims-based performance status 
 
Appendix 3.6 Multivariable generalized linear model assessing total healthcare costs, 
medical costs and prescription drug costs mRCC patients who received CN + targeted 
therapy versus targeted therapy alone 
 
Average costs per 
month 
CN + targeted therapy  
(n = 154) 
Mean (95%CI) 
Targeted therapy alone  
(n = 326) 
Mean (95%CI) 
p-value 
Total healthcare costs 16,680 (13,578 - 20,491)  22,677 (18,907 - 27,199) 0.0003 
Medical costs 14,244 (11,197 - 18,121) 12,992 (9,956 - 16,954) 0.4215 
Prescription drug costs 3,318 (2,365 - 4,655)  6,932 (5,208 - 9,229) <0.0001 
Note: Covariates included age, gender, race, marital status, zip code level income, zip code level 
education, SEER region, urban rural status, NCI comorbidity index, tumor size, tumor grade, 
tumor extent (T), lymph node extent (N), cell type, era of diagnosis, metastases to liver / 
lung/bone/brain, claims-based performance status 
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Appendix 3.7 Predictors of receiving targeted therapy among older mRCC patients. 
Characteristics Total  
(n = 1,263) 
n (%) 
Tagreted therapy use Odds Ratio 
 (95 % CI) 
Yes  
(n = 561) 
No 
(n = 702) 
Age at diagnosis (years)   
- 65-69 
- 70-74 
- 75-79 
- 80 or more 
 
293 (23) 
346 (27) 
297 (24) 
327 (26) 
 
170 (30) 
190 (34) 
133 (24) 
68 (12) 
 
123 (18) 
156 (22) 
164 (23) 
259 (37) 
 
Reference 
0.95 (0.68 - 1.35) 
0.69 (0.48 - 0.99)* 
0.26 (0.18 - 0.39)* 
Sex  
- Male 
- Female 
 
690 (55) 
573 (45) 
 
336 (60) 
225 (40) 
 
354 (50) 
348 (50) 
 
1.12 (0.85 - 1.47) 
Reference  
Race/Ethnicity  
- White 
- Black /others 
 
1083 (86) 
180 (14) 
 
482 (86) 
79 (14) 
 
601 (86) 
101 (14) 
 
0.84 (0.58 - 1.22) 
Reference 
Marital status  
- Married 
- Single/Divorced/Separated 
 
610 (48) 
653 (52) 
 
316 (56) 
245 (44) 
 
294 (42) 
408 (58) 
 
1.50 (1.14 - 1.97)* 
Reference 
Zip code- college educated  
- 0 to 15% 
- 16-20% 
- 21-30% 
- 31% and above 
 
366 (29) 
217 (17) 
279 (22) 
401 (32) 
 
147 (26) 
94 (17) 
121 (22) 
199 (35) 
 
219 (31) 
123 (18) 
158 (23) 
202 (29) 
 
Reference  
1.31 (0.87 - 1.97) 
1.32 (0.87 - 1.99) 
1.55 (0.96 - 2.49) 
Zip code level median 
household income (USD)  
- < 40k 
- 40k - 50 k  
- 51k - 70k 
- > 70 k 
 
 
301 (24) 
300 (24) 
358 (28) 
304 (24) 
 
 
124 (22) 
123 (22) 
163 (29) 
151 (27) 
 
 
177 (25) 
177 (25) 
195 (28) 
153 (22) 
 
 
Reference 
0.76 (0.51 - 1.14) 
0.86 (0.56 - 1.32) 
0.91 (0.52 - 1.57) 
Urban/Rural Status  
- Big Metro 
- Metro /Urban 
- Less urban / Rural  
 
595 (47) 
482 (38) 
186 (15) 
 
262 (47) 
218 (39) 
81 (14) 
 
333 (47) 
264 (39) 
105 (14) 
 
0.98 (0.62 - 1.53) 
0.94 (0.62 - 1.44) 
Reference  
SEER region  
- Northeast 
- South 
- North Central  
- West  
 
218 (17) 
349 (28) 
168 (13) 
528 (42) 
 
93 (17) 
154 (27) 
67 (12) 
247 (44) 
 
125 (18) 
195 (28) 
101 (14) 
281 (40) 
 
Reference  
1.29 (0.83 - 2.00) 
0.98 (0.59 - 1.62) 
1.29 (0.89 - 1.87) 
Year of diagnosis  
 - 2007 to 2009 
 - 2010 to 2013 
 
525 (42) 
738 (58) 
 
206 (37) 
355 (63) 
 
319 (45) 
383 (55) 
 
Reference 
1.48 (1.13 - 1.93)* 
NCI comorbidity index 
(mean, SD) 
 
1.47 (1.8) 
 
1.21 (1.4) 
 
1.68 (1.9) 
 
0.86 (0.78 - 0.95)* 
NCI comorbidity index score  
 - 0  
 - 1 
 - 2 
 - 3 or more  
 
476 (38) 
337 (27) 
169 (13) 
281 (22) 
 
225 (40) 
173 (31) 
65 (12) 
98 (17) 
 
251 (36) 
164 (23) 
104 (15) 
183 (26) 
 
NA 
Note: Odds ratios were calculated from multivariable logistic regression 
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Appendix 3.7 Continued 
Characteristics Total (n = 1,263) 
n (%) 
Tagreted therapy use Odds Ratio 
 (95 % CI) 
Yes No 
Histology  
- Clear cell 
- Non clear cell 
 
1,148 (91) 
115 (9) 
 
507 (90) 
54 (10) 
 
641 (91) 
61 (9) 
 
1.13 (0.73 - 1.74) 
Reference  
Tumor size  
- Unknown / < 5 cm 
- 5 to 7.9 cm 
- ≥ 8 cm 
 
460 (36) 
327 (26) 
476 (38) 
 
169 (30) 
144 (26) 
248 (44) 
 
291 (41) 
183 (26) 
228 (32) 
 
Reference  
1.05 (0.74 - 1.47) 
1.21 (0.83 - 1.75) 
Tumor grade  
- Well/ moderate 
- Poor / undifferentiated  
- Unknown 
 
130 (10) 
244 (19) 
889 (70) 
 
86 (15) 
136 (24) 
339 (60) 
 
44 (6) 
108 (15) 
550 (78) 
 
Reference  
0.50 (0.30 - 0.83)* 
0.42 (0.27 - 0.65)* 
Tumor extent (T) - TNM  
  -  T0 / T1/ unknown 
  -  T2  
  -  T3  
  -  T4 
 
603 (48) 
183 (15) 
359 (28) 
118 (9) 
 
217 (39) 
91 (16) 
201 (36) 
52 (9) 
 
386 (55) 
92 (13) 
158 (23) 
66 (9) 
 
Reference 
1.21 (0.78 - 1.89) 
1.46 (1.03 - 2.08) 
1.19 (0.74 - 1.94) 
Lymph Node (N) - TNM  
 - N0 /NX 
 - N1 /N2  
 
949 (75) 
314 (25) 
 
403 (72) 
158 (28) 
 
546 (78) 
156 (22) 
 
0.77 (0.58 - 1.89) 
Reference  
Bone metastasis 
- Absent 
- Present  
 
750 (59) 
513 (41) 
 
327 (58) 
234 (42) 
 
423 (60) 
279 (40) 
 
Reference  
1.22 (0.93 - 1.60) 
Lung metastasis 
- Absent 
- Present 
 
573 (45) 
690 (55) 
 
244 (44) 
317 (57) 
 
329 (47) 
373 (53) 
 
Reference 
0.97 (0.74 - 1.26) 
Liver metastasis  
- Absent 
- Present 
 
1,004 (79) 
259 (21) 
 
465 (83) 
96 (17) 
 
529 (77) 
163 (23) 
 
Reference 
0.65 (0.47 - 0.90)* 
Brain metastasis  
- Absent 
   - Present 
 
1,086 (86) 
177 (14) 
 
493 (88) 
68 (12) 
 
593 (84) 
109 (16) 
 
Reference 
0.55 (0.39 - 0.81)* 
Performance status 
indicators  
Average number of services 
 - ED visits  
 - hospital days 
 - physician claims 
 - home health claims 
 
DME use (Yes vs No) 
Assisting devices (Yes vs No) 
 
 
 
3.5 (3.2) 
1.16 (5.3) 
33.2 (30.4) 
0.24 (0.8) 
 
487 (39) 
240 (19) 
 
 
 
4.0 (3.4) 
0.53 (2.0) 
30.8 (25.0) 
0.12 (0.6) 
 
199 (35) 
96 (17) 
 
 
 
3.1 (2.9) 
1.65 (6.9) 
35.2 (34.0) 
0.33 (0.9) 
 
288 (41) 
144 (21) 
 
 
 
1.15 (1.10 - 1.21)* 
0.94 (0.90 - 0.98)* 
1.00 (0.99 - 1.01) 
0.76 (0.62 - 0.94)* 
 
0.98 (0.69 - 1.75) 
1.15 (0.76 - 1.21) 
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Appendix 3.8 Overall survival between mRCC patients that received targeted therapy versus 
patients who did not 
 
A) Unadjusted  
 
B) IPTW adjusted method 
 
88 
 
References 
1. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 
2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-
and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. 
2. Kirchner H, Strumberg D, Bahl A, Overkamp F. Patient-based strategy for systemic treatment 
of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2010;10:585-596. 
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29. 
4. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA 
Cancer J Clin. 2007;57:112-125. 
5. Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell 
carcinoma? Clin Genitourin Cancer. 2005;4:181-186. 
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-
cell carcinoma. N Engl J Med. 2007;356:115-124. 
7. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell 
carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-
456. 
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. 
N Engl J Med. 2007;356:125-134. 
9. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal 
cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068. 
89 
 
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced 
renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. 
11. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. 
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 
2004;171:1071-1076. 
12. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-
2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 
2001;345:1655-1659. 
13. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for 
Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus 
interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell 
carcinoma: a randomised trial. Lancet. 2001;358:966-970. 
14. Tsao CK, Small AC, Kates M, et al. Cytoreductive nephrectomy for metastatic renal cell 
carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 
2013;31:1535-1539. 
15. Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and 
patient survival in the targeted therapy era. Int J Cancer. 2014;134:2245-2252. 
16. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous 
metastases from renal cell carcinoma: results from the International Metastatic Renal Cell 
Carcinoma Database Consortium. Eur Urol. 2014;66:704-710. 
90 
 
17. Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal 
Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A 
National Cancer Data Base Study. J Clin Oncol. 2016;34:3267-3275. 
18. Macleod LC, Odisho AY, Tykodi SS, Holt SK, Harper JD, Gore JL. Comparative 
Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the 
Targeted Therapy Era: Analysis of a Population-based Cohort. Urology. 2017. 
19. Banegas MP, Harlan LC, Mann B, Yabroff KR. Renal cell cancer: a shift in approaches for 
treatment of advanced disease in the United States. J Natl Compr Canc Netw. 2014;12:1271-
1279. 
20. Harrison MR, Hirsch BR, George DJ, et al. Real-world outcomes in metastatic renal cell 
carcinoma: insights from a Joint Community-Academic Registry. J Oncol Pract. 2014;10:e63-
72. 
21. Hollenbeak CS, Nikkel LE, Schaefer EW, Alemao E, Ghahramani N, Raman JD. 
Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma. J 
Manag Care Pharm. 2011;17:610-620. 
22. High Priced Drugs: Estimates of Annual per Patient Expenditures for 150 Specialty 
Medications - Issue Brief. AHIP. American Health Insurance Plans; 2016. Available from: 
https://www.ahip.org/report-high-priced-drugs-expenditures/highpricedrugsreport/. Accessed 
12/12/2016. 
23. SEER-Medicare: SEER program & Data. Available at: 
https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/program.html. Accessed 12/14, 
2016. 
91 
 
24. SEER Fact Sheets and Brochure. Available at: 
https://seer.cancer.gov/about/factsheets/SEER_brochure.pdf. Accessed 12/15, 2016. 
25. Andersen RM. Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? 
J Health Soc Behav. 1995;36:1-10. 
26. Andersen R, Newman JF. Societal and Individual Determinants of Medical Care Utilization 
in the United States. Milbank Q. 2005;83 
27. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in 
epidemiology. Epidemiology. 2000;11:550-560. 
28. Austin PC. The relative ability of different propensity score methods to balance measured 
covariates between treated and untreated subjects in observational studies. Med Decis Making. 
2009;29:661-677. 
29. Archived Consumer Price Index Detailed Reports. Available at: 
https://www.bls.gov/cpi/tables/detailed-reports/home.htm#. Accessed 12/10, 2017. 
30. Saigal CS, Deibert CM, Lai J, Schonlau M. Disparities in the treatment of patients with IL-2 
for metastatic renal cell carcinoma. Urol Oncol. 2010;28:308-313. 
31. Mejean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic 
Renal-Cell Carcinoma. NEJM  2018 DOI: 10.1056/NEJMoa1803675 
32. Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy 
for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011;18:2988-
2996. 
92 
 
33. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do 
patients and their oncologists agree? Br J Cancer. 2003;89:1022-1027. 
34. Salloum RG, Smith TJ, Jensen GA, Lafata JE. Using claims-based measures to predict 
performance status score in patients with lung cancer. Cancer. 2011;117:1038-1048. 
35. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models 
of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a 
population-based study. Lancet Oncol. 2013;14:141-148. 
36. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative 
treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 
2002;20:289-296. 
37. Measures that are Limited or not Available in the Data. Available 
at:https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html#16. 
Accessed 10/10, 2017. 
 
 
 
 
 
 
 
93 
 
Chapter 4 
Study 3: Prescribing Patterns of Targeted Therapies, Overall Survival, and Total Healthcare 
Cost among Older Adults with Metastatic Renal Cell Carcinoma in the U.S 
 
ABSTRACT 
OBJECTIVES  
Several targeted therapies have been approved since 2005 to treat metastatic renal cell 
carcinoma (mRCC). The first aim of this study was to describe prescribing patterns of targeted 
therapies among mRCC patients. The second aim was to describe overall survival (OS) and total 
healthcare costs (THC) for commonly observed targeted therapy patterns.  
METHODS 
This study analyzed 2007-2014 Surveillance Epidemiology and End Result (SEER)-
Medicare data. Patients with mRCC were defined as those who were diagnosed at stage-IV as well 
as those who were diagnosed at earlier stages but were currently using targeted therapies. Further, 
we restricted our sample to patients who initiated targeted therapy and were continuously enrolled 
in Medicare Fee for Service plans. We described the frequencies of the most commonly used first 
and second line targeted therapies for clear-cell and non-clear cell mRCC. We also described the 
most frequently used sequences among patients who received two or more lines of targeted 
therapies. Oral targeted therapies were identified using generic names and National Drug Codes. 
Injectable targeted therapies were identified using the HealthCare Common Procedure Coding 
System (HCPCS) codes. Median OS and THC per month were described for the most common 
treatment patterns from the date of the first targeted therapy prescription until the end of 2014 or 
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until death. Median OS was calculated using Kaplan Meier survival curves. All analyses were 
conducted using SAS v.9.4.   
RESULTS 
 Of 915 patients, 521 (57%) used only one line, 240 (26%) used two lines and 154 (17%) 
used three or more lines of targeted therapies. Among clear cell mRCC patients, sunitinib (384, 
48%) and everolimus (101, 13%) were the most commonly used first and second line targeted 
therapies. Of 109 non-clear cell patients, sunitinib (n = 35, 32%) and temsirolimus (n = 26, 24%) 
were the most commonly prescribed first line targeted therapies. Only 44 non-clear cell mRCC 
patients received second line therapies. Among patients who received multiple lines, VEGF-
mTOR was the most commonly prescribed sequence. The median OS was 6.0 months, 13.7 months 
and 23.7 months for patients with clear cell mRCC who received one line, two lines and 3 or more 
lines of targeted therapies respectively. The median monthly THC was significantly higher (p < 
0.05) for patients who received only one line of therapy ($ 14,243) than patients who received two 
lines ($ 9,985) and three or more lines of therapies ($ 10,110). The median OS and median monthly 
THC was similar across targeted therapy sequences. 
CONCLUSIONS 
 About fifty percent of mRCC patients who had at least one targeted therapy received 
multiple lines of therapies. Sunitinib and everolimus were the most common first and second line 
targeted therapies among mRCC patients. The descriptive analysis suggested that OS and THC 
were similar across targeted therapy sequences. 
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BACKGROUND 
Metastatic renal cell carcinoma (mRCC) is a deadly disease with a 5-year survival rate of 
about 12%.1 About 15%-20% of RCC patients are diagnosed at the metastatic stage and about 30-
33% of patients diagnosed at early stages eventually progress to the metastatic stage. The median 
age of RCC diagnosis is 64 years and Medicare covers about 46% of total RCC patients in the 
U.S.2, 3  
In the last 15 years, systemic therapy has become the main treatment for mRCC patients. 
Before 2005, systemic therapy mainly included cytokines such as high dose interleukin-2 and 
interferon-alpha. However, both drugs were associated with low tumor response rates, high 
toxicity, and improvement of less than 6-12 months in overall survival (OS).4, 5 In 2005, the first 
targeted therapy, sorafenib, was approved by the U.S Food and Drug Administration (FDA) to 
treat mRCC. Since then, several additional targeted therapies have become available to treat 
mRCC.6-10 These include vascular endothelial growth factor inhibitors (VEGFi) like the tyrosine 
kinase inhibitors (TKI) sunitinib, pazopanib, and axitinib; the mammalian target of rapamycin 
inhibitors (mTORi) everolimus and temsirolimus; and the anti-VEGF monoclonal antibody 
bevacizumab. While most of the targeted therapies are approved as first and second line therapies, 
everolimus and axitinib are approved only as second-line therapies. Patients treated with first-line 
targeted therapy often develop resistance within 6-11 months and as a result, need subsequent lines 
of therapy to control disease progression. 6, 8 
The availability of several options has complicated decision making regarding the optimal 
choice of targeted therapy to treat mRCC patients. The National Comprehensive Cancer Network 
(NCCN) develops evidence-based guidelines to help healthcare professionals to decide appropriate 
treatment strategies for cancer patients.11, 12 A category-1 recommendation indicates uniform 
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consensus about appropriateness of the intervention among NCCN panel members based on a 
high-level of evidence; Category-2A indicates uniform consensus based on a lower level of 
evidence; category-2B indicates some consensus based on lower level of evidence and category-3 
indicates major disagreement about appropriateness of intervention.  In the targeted therapy era, 
NCCN guidelines included sunitinib, pazopanib, and bevacizumab/interferon as category-1 
recommendations and sorafenib as Category-2A recommendation for first-line treatment. 
Recommendations for second line therapy included all of the above agents and everolimus. 
However, only axitinib and everolimus have a Category-1 recommendation as second-line 
treatments while other agents have either category 2-A or 2-B recommendation. No 
recommendations were made for the use of third-line targeted therapies.11, 12 
Several studies have analyzed prescribing patterns of targeted therapies among mRCC 
patients.13-17 Miller et al. (2016) examined targeted therapy patterns using Humana claims data and 
assessed their consistency with the NCCN guidelines. They found that the largest proportion of 
patients received sunitinib (44%) as first and everolimus (29%) as second-line therapy; both have 
category-1 recommendations. Most treatment patterns were consistent with the NCCN 
recommendations for first-line therapy, but 5% of patients received everolimus as first-line, nearly 
20% received bevacizumab as second line, and 15% received temsirolimus as second-line 
therapies.15 These have a lower level of evidence (category 2-B) according to NCCN guidelines. 
Bevacizumab is approved by the FDA and recommended to be given in combination with 
interferon-α. However, several patients who received bevacizumab did not receive interferon-α. 
Similar findings regarding the most common first and second-line treatments were reported by two 
other studies.14, 17  
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A majority of previously published studies were conducted using commercial claims data 
and included patients diagnosed at younger ages. A number of them compared utilization of 
individual drug therapies, mainly sunitinib and pazopanib, but few described patterns that covered 
the entire therapeutic landscape. Few studies were conducted among older mRCC patient on 
Medicare.18 Pal et al. (2017) compared survival among Medicare patients receiving first-line 
targeted therapies. The authors found that patients diagnosed in the late-targeted therapy era (2010-
2012) had significantly higher OS than patients from the early- targeted therapy era (2006-2009). 
Additionally, patients prescribed pazopanib had higher OS than patients on sunitinib and 
sorafenib.20 The study, however, did not describe second or subsequent lines of therapies. Rasca 
et al. (2015) compared prescribing patterns and survival among patients from Medicare Advantage 
plans. In contrast to Pal et al., no significant difference in OS was observed among sunitinib and 
pazopanib users.19 Older adults with mRCC represent a special population for study because they 
are under-represented in randomized controlled trials. Additionally, comorbid conditions and 
frailty can complicate their treatment and may affect health outcomes. In addition, Medicare is the 
single largest payer for RCC patients, covering about 46% of them. The high costs of targeted 
therapies, which range from US $6,000 to $15,000 per month and the costs of managing adverse 
events and complications, may result in a significant economic burden on Medicare. The first aim 
of this study was to describe patterns of first line and subsequent lines of targeted therapies among 
older mRCC patients. The second aim was to describe the overall survival and healthcare costs for 
the first and the subsequent line targeted therapy users. 
METHODS 
Data Source 
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SEER-Medicare 
We used 2007-2014 SEER-Medicare data. The Patient Entitlement and Diagnosis 
Summary File was used to obtain demographics and cancer diagnosis-related information. 
Resource use and cost-related information were obtained from Medicare Provider Analysis and 
Review (MEDPAR), outpatient, carrier, Part D event (PDE), home health agencies (HHA), 
hospice (HS) and durable medical equipment (DME) files. The MEDPAR file was used to obtain 
inpatient hospital and skilled nursing facility (SNF) claims. The HS file provided data on hospice 
care utilization. The carrier file provided information on non-institutional physician-provided 
services whereas the outpatient file provided information on institutional physician-provided 
services. The PDE file provided data related to prescription medication use (Medicare Part D). 
DME files provided data on the use of durable medical equipment while HHA files were used to 
get information on services provided in patients’ homes.20 
Study Design and Sample Selection 
This was a retrospective cohort study. The study first identified patients with an incident 
diagnosis of RCC using the International Classification of Diseases for Oncology, 3rd edition codes 
C64.9 and relevant histology types ('8260', '8310', '8312', '8316', '8317', '8318'). Patients who 
initiated any systemic therapy between January 2007 and December 2013 were included in the 
study.  The index date was defined as the date of the first prescription for a newly initiated systemic 
therapy. We excluded patients aged < 65 years, diagnosed with another cancer at the time of RCC 
diagnosis, diagnosed on autopsy, having cancer reported by death certificate, or enrolled in health 
maintenance organizations (HMOs). Figure 1 depicts the sample selection process. Treatment 
patterns and overall survival (OS) were measured in the follow-up period, which began after the 
index date and continued until death or the end of study period (end of December 2014). Total 
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healthcare cost (THC) over the lifetime was assessed among patients that had complete follow up 
until death. For cost analyses, patients who were still alive at the end of the study period were 
excluded. Baseline characteristics were assessed in the 1-year period prior to the index prescription 
date.  
Oral targeted therapies were identified using generic names and National Drug Codes 
(NDCs) from Medicare Part D. Injectable-targeted therapies were identified using Healthcare 
Procedural Codes (HCPC) from Medicare Part B data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
Figure 4.1 Sample selection process for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE: For cost analysis, we excluded an additional 231 patients due to incomplete follow-up 
period from index date until death as these patients continued to live beyond December 2014. 
 
 
Registry confirmed first primary 
RCC diagnosis using ICD-O codes 
C.64.9 
(n = 35,184) 
• Patients aged < 65 years (n = 
12,444) 
• Diagnosed on autopsy (n = 171) 
• Missing date of diagnosis (n = 
136) 
• Not continuously enrolled in 
Medicare Parts A and B (n = 
3,317) 
• Had HMO coverage (n = 7,073) 
• Not continuously enrolled in Part 
D prescription drug plan (n = 
5,714) 
Kidney cancers other than 
RCC and patients with 
multiple cancers  
(n =22,476) 
 
SEER-Medicare population 
diagnosed with kidney and renal 
pelvis cancer from January 2007 to 
December 2013 
(n = 57,660) 
RCC patients diagnosed at age ≥ 65 
years with continuous Medicare 
Parts A, B and D enrollment 
(n = 6,329) 
 
 
 
Cohort of targeted therapy users 
after RCC diagnosis  
(n = 915) 
 
 
• Patients with no targeted therapy 
record (n = 5,336) 
• Patients with targeted therapy 
use before diagnosis (n = 78) 
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Figure 4.2. Diagrammatic representation of study design 
 
 
 
 
Study Measures 
Prescribing patterns 
Prescribing patterns included identification of the most common first line therapies. For 
patients who received more than one line, we identified the most common second line therapies. 
In addition, the most common treatment sequences were identified. Patterns were assessed 
separately for patients who had clear-cell and non-clear cell RCC. 
Overall Survival 
The study defined overall survival as the time in months from the date of the index 
prescription until the date of death or until the end of the study period. Patients that were alive 
beyond the follow-up period were censored.  
Healthcare cost 
 Costs were the amounts reimbursed by Medicare for healthcare services. Costs for each 
component were calculated and aggregated to calculate total healthcare costs (THC). Costs were 
presented as monthly costs. All costs were converted to 2016 US dollars using the Consumer Price 
Index for medical care services and medical care commodities.21 
Other variables  
Examination of prescribing patterns and survival  
  
Follow-up period until death or until the end of study period 12 months 
 Baseline period  
Date of first prescription for a targeted 
therapy initiation 
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 These variables included patient demographics, geographical region, tumor characteristics, 
site of metastasis, cancer staging specific details, histology, and the National Cancer Institute’s 
(NCI) comorbidity index. Information on these variables was obtained in the baseline period.  
Statistical Analysis 
Sample characteristics were described using basic descriptive statistical procedures. The 
median overall survival for the most common treatment patterns and sequences was calculated 
using Kaplan Meier curves and Log-rank tests. Healthcare costs were described as mean and 
median costs per month. All analyses were conducted at an α level of 0.05 using SAS v.9.4 (SAS 
Institute Inc, Cary, NC) and Microsoft Excel 2016. 
 
RESULTS 
Sample Characteristics 
 The final study sample included 915 RCC patients who were prescribed at least one 
targeted therapy. About 58% patients were aged between 65-74 years, 61% were males, 85% were 
white and 56% were married or lived with a partner. About 47% patients lived in big metropolitan 
area, and in the  West (47%). About 60% of patients were diagnosed in the later part of the targeted 
therapy era (2010-2013). About 68% had one or more comorbidities. A majority of patients were 
diagnosed at stage-IV (60%) while 40% were diagnosed at earlier stages. These patients were 
assumed to have the recurrent metastatic disease. The vast majority of patients (88%) had clear 
cell RCC while only 12% had non-clear cell RCC.  
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Table 4.1 Characteristics of older RCC patients who received at least one targeted therapy 
Characteristics Total (n = 915) 
Frequency n (%) 
Age at diagnosis (years)   
- 65-69 
- 70-74 
- 75-79 
- 80 or more 
 
264 (29) 
264 (29) 
214 (23) 
173 (19) 
Sex  
- Male 
- Female 
 
560 (61) 
355 (39) 
Race/Ethnicity  
- White 
- Black /others 
 
778 (85) 
137 (15) 
Marital status  
- Married 
- Single/Divorced/Separated 
 
515 (56) 
400 (44) 
Zip code- college educated  
- 0 to 15% 
- 16-20% 
- 21-30% 
- 31% and above 
 
260 (29) 
146 (16) 
184 (20) 
325 (36) 
Zip code level median household income (USD)  
- < 40k 
- 40k - 50 k  
- 51k - 70k 
- > 70 k 
 
206 (23) 
187 (20) 
276 (30) 
246 (27) 
Urban/Rural Status  
- Big Metro 
- Metro /Urban 
- Less urban / Rural  
 
431 (47) 
350 (38) 
134 (15) 
SEER region  
- Northeast 
- South 
- North Central  
- West  
 
156 (17) 
229 (25) 
104 (11) 
426 (47) 
Year of diagnosis  
 - 2007 to 2009 
 - 2010 to 2013 
 
367 (40) 
548 (60) 
NCI comorbidity index score  
 - 0  
 - 1 
 - 2 
 - 3 or more  
 
350 (38) 
262 (29) 
121 (13) 
182 (20) 
Stage at diagnosis 
- I 
- II 
- III 
- IV 
- Unstaged 
 
111 (12) 
36 (4) 
175 (19) 
553 (60) 
40 (4) 
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Table 4.1 Continued 
Characteristics Frequency n (%) 
Histology  
- Clear cell 
- Non clear cell 
 
806 (88) 
109 (12) 
Tumor size  
- Unknown / < 5 cm 
- 5 to 7.9 cm 
- ≥ 8 cm 
 
290 (32) 
250 (27) 
375 (41) 
Tumor grade  
- Well/ moderate 
- Poor / undifferentiated  
- Unknown 
 
211 (23) 
305 (33) 
399 (44) 
Tumor extent (T) - TNM  
  -  T0 / T1/ unknown 
  -  T2  
  -  T3  
  -  T4 
 
351 (38) 
128 (14) 
375 (41) 
61 (7) 
Lymph Node (N) - TNM  
 - N0 /NX 
 - N1 /N2  
 
721 (79) 
194 (21) 
Metastasis (M) - TNM  
- M0 /MX 
 - M1 
 
388 (42) 
527 (58) 
 
Lines of Therapies  
Of 915 patients, 521 (57%) used only one line, 240 (26%) used two lines and 154 (17%) 
used three or more lines of therapies. This distribution was similar for clear cell and non-clear 
cell RCC patients. 
First and second line therapies among clear cell RCC patients 
 Of 806 clear-cell mRCC patients that received at least one targeted therapy, 384 (48%) 
received sunitinib, 139 (17%) received temsirolimus, 128 (16%) received pazopanib, and 71 (9%) 
received sorafenib as first-line therapy. A total of 350 patients received 2nd line therapy. Of 2nd line 
therapy users, 101 (29%) received everolimus and 84 (24%) patients received temsirolimus. 
Approximately equal proportion of patients (10-11%) received sorafenib, sunitinib, and 
pazopanib. (Table 2.)  
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First and second line therapies among non-clear cell RCC patients 
 Of 109 non-clear cell patients, sunitinib (n = 35, 32%), temsirolimus (n = 26, 24%), and 
bevacizumab (n = 18, 17%) were the most commonly prescribed first line targeted therapies. Only 
44 patients received second line therapies. Temsirolimus, sunitinib, and everolimus were the most 
common second line therapies (n < 11). 
Common sequences of targeted therapies among clear cell RCC patients 
 Of 350 patients that received two or more lines of therapies, the top five sequences 
included: - 1) sunitinib followed by everolimus (8%) 2) sunitinib followed by temsirolimus (6%) 
3) sunitinib followed by sorafenib (5%) 4) pazopanib followed by everolimus (4%) and 5) sunitinib 
followed by pazopanib (4%). In terms of therapeutic classes, VEGF - mTOR (25%), VEGF-VEGF 
(21%), VEGF-mTOR-VEGF (11%), mTOR- VEGF (9%) and VEGF-VEGF-mTOR (6%) were 
the most common sequences.  
Common sequences of targeted therapies among non-clear cell RCC patients 
 Only 44 patients received two or more lines of therapies. Temsirolimus followed by 
sunitinib (n<11) and temsirolimus followed by bevacizumab (n<11) were the top two sequences. 
In terms of therapeutic class, an equal proportion of patients received VEGF-mTOR and mTOR-
VEGF.  
Overall Survival (OS) 
 Median OS by the number of lines of therapies for clear cell and non-clear cell patients is 
described in Table 2 and Table 3 respectively. In the descriptive analysis, patients with clear cell 
RCC who received two lines of therapies had higher median OS than patients who received only 
one line. Similarly, patients who received 3 or more lines had higher OS than patients receiving 
one or two lines of targeted therapies.  We also examined time since diagnosis for each group to 
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understand if there was any survivorship bias. The median time since diagnosis was 121 days for 
patients receiving one line of therapy, 106 days for patients receiving two lines, and 118 days for 
patients receiving three lines (p= 0.1933) Time since diagnosis also did not differ by number of 
line of therapies prescribed for patients that were directly diagnosed at stage-IV and patients 
diagnosed at earlier stages.  
Kaplan Meier analysis suggested that pazopanib had significantly higher OS than 
sorafenib, sunitinib and temsirolimus (p <0.05). Sunitinib followed by pazopanib had a median 
OS of 20.7 months compared to 13.7 months for sunitinib followed by everolimus. However, this 
difference was not statistically significant. Among patients who received multiple lines of 
therapies, no particular drug or a class sequence resulted in a significantly higher OS compared 
to other sequences. (Table 4.2) 
 Among non-clear cell RCC patients, those who received two or more lines of targeted 
therapies had higher OS than patients receiving a single line of targeted therapy. However, the 
difference in OS was not statistically significant. Time since diagnosis was 166 days for patients 
receiving one line of therapy, 112 for patients receiving two lines, and 121 days for patients 
receiving three lines (p = 0.3547). Time since diagnosis also did not differ by a number of line of 
therapies prescribed for patients that were directly diagnosed at stage-IV and patients diagnosed 
at earlier stages. Since very few non-clear cell RCC patients received two or more lines of 
therapies, we did not describe OS by drug-level sequencing. In terms of class-level sequence, 
patients who received mTOR-VEGF and VEGF-mTOR had similar median OS. (Table 4.3). 
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Table 4.2 Overall survival among clear cell Renal Cell Carcinoma patients receiving 
targeted therapy 
 
 Median Overall 
Survival (months) 
95%CI 
Number of lines *   
First line only (n = 456) 6.0 5.0 - 7.0 
First and second line (n = 212) 13.7 11.8 - 15.2 
Three or more lines (n = 138) 23.7 20.3 - 26.0 
First line therapy users    
• Sunitinib (n = 214) 
• Sorafenib (n = 42) 
• Pazopanib (n = 65) 
• Bevacizumab (n = 50) 
• Temsirolimus (n = 74) 
3.9 
5.6 
9.4 
NA 
5.2 
2.8 - 5.1 
2.9 - 6.8 
6.6 - 20.8 
NA 
4.0 -7.1 
Most common drug sequences   
• Sunitinib-Everolimus (n = 28) 
• Sunitinib-Temsirolimus (n = 20) 
• Sunitinib - Sorafenib (n = 19) 
• Sunitinib-Pazopanib (n = 14) 
• Pazopanib - Everolimus (n = 14) 
13.7 
11.6 
13.9 
20.7 
13.7 
7.6 - 21.2  
7.4 - 17.2 
7.5 - 22.3 
NA 
7.1 - 22.4 
Most common class sequences   
• VEGF-mTOR (n = 88) 
• VEGF-VEGF  (n = 73) 
• VEGF-mTOR-VEGF (n = 39) 
• mTOR-VEGF (n = 31) 
• VEGF-VEGF-mTOR (n = 20) 
13.9 
15.1 
18.0 
10.5 
17.8 
11.3 - 16.5 
11.9 - 18.2 
14.4 - 22.7 
5.4 - 20.4 
13.0 - 25.7 
NA: median survival or confidence intervals were not available due to a higher frequency of 
censoring.   
** Statistically significant, p<0.05 
Following comparisons were statistically significant:  
First line therapy only: Sunitinib vs pazopanib, sorafenib vs pazopanib, temsirolimus vs 
pazopanib 
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Table 4.3 Overall survival among non-clear cell Renal Cell Carcinoma patients receiving 
targeted therapy 
Note: OS is not shown for drug sequences because all had n< 11  
NA: median survival or confidence intervals were not available due to a higher frequency of 
censoring.  
NS: not statistically significant   
 
Total Healthcare Costs 
 Among clear cell RCC patients, median monthly total healthcare cost was higher among 
patients who received only one line of targeted therapy compared to patients who received multiple 
lines of therapies. Patients who received two lines and three or more lines of therapies had similar 
total healthcare costs. Among patients who received only one line of therapy, the median monthly 
total healthcare cost was highest for sunitinib users. Wilcoxon Mann Whitney tests indicated that 
median monthly THC for sunitinib users was significantly higher than for bevacizumab, 
temsirolimus and pazopanib users (p<0.05). Sorafenib, temsirolimus and pazopanib users had 
similar total healthcare costs whereas bevacizumab users had lowest total healthcare costs. For 
patients who received two or more sequences, median monthly total healthcare costs were similar 
for all the targeted therapy sequences. (Table 4.4)   
Among non-clear cell RCC patients, median monthly total healthcare cost was higher 
 Overall Survival in months 
Median 
95%CI 
Number of lines NS   
First line only (n = 65) 6.4 3.9 - 14.1 
First and second line (n = 28) 11.6 7.6 - 13.0 
Three or more lines (n = 16) 16.3 9.3 - 19.3 
First line therapy users 
• Sunitinib (n = 25) 
• Bevacizumab (n =17)  
• Temsirolimus (n = 11) 
 
5.2 
54.6 
3.4 
 
2.7 - 11.3 
NA 
1.3 - 4.2 
Most common class sequences 
• mTOR-VEGF (n = 12) 
• VEGF-mTOR (n<11) 
 
14.0 
10.4 
 
7.6 - 31.3 
7.3 - 12.8 
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among patients who received only one line than for patients who received multiple lines of 
therapies. No other cost differences were statistically significant.  
 
Table 4.4 Total healthcare costs per month among clear cell Renal Cell Carcinoma patients 
receiving targeted therapy 
 
 Mean (SD) 
US $ 
Median (IQR: Q1 - Q3) 
US $ 
Number of lines    
• First line only (n = 336) 
• First and second line (n = 164) 
• Three or more lines (n = 105) 
20,837 (20,987) 
11,866 (6,785) 
10,998 (4,851)  
14,243 (8,402 - 25,306) 
9,985 (7,579 - 14,080) 
10,110 (7,710 - 12,754)  
First line therapy users    
• Sunitinib (n = 179) 
• Temsirolimus (n = 64) 
• Sorafenib (n = 38) 
• Pazopanib (n = 34) 
• Bevacizumab (n = 12) 
23,750 (21,169) 
16,098 (16,605) 
21,078 (22,874) 
19,696 (27,524) 
9,788 (6,032) 
16,976 (10,000 - 31,891)    
10,592 (6,696 - 19,215)    
14,347 (8,776- 19,176)    
12,141 (7,751 - 18,382)    
9,254 (4,523 - 13,150)    
Most common drug sequences   
• Sunitinib-Everolimus (n = 22) 
• Sunitinib-Temsirolimus (n = 18) 
• Sunitinib - Sorafenib (n = 16) 
• Pazopanib - Everolimus (n = <11) 
• Sunitinib-Pazopanib (n = <11) 
12,237 (7,553)          
11,380 (6,008)          
9,351 (4,429)           
10,243 (2,913) 
14,448 (7,157)                   
10,429 (7,428 - 13,205) 
10,712 (8,006 - 12,210) 
7,760 (5,960- 13,584) 
10,405 (7,749 - 11,952) 
12,266 (9,079 - 20,237) 
Most common class sequences   
• VEGF-mTOR (n = 71) 
• VEGF-VEGF  (n = 49) 
• VEGF-mTOR-VEGF (n = 35) 
• mTOR-VEGF (n = 26) 
• VEGF-VEGF-mTOR (n = 15) 
11,516 (6,056) 
10,888 (4,925) 
11,227 (3,773)          
15,519 (9,901) 
11,101 (2,748)                                      
10,724 (7,428 - 13,283)  
9,481 (7,532 - 13,621) 
10,313 (8,782 - 13,665) 
12,790 (9,170 - 18,447) 
11,598 (9,689 - 12,676) 
 
Note: Significant differences were observed for following comparisons 
Number of lines: One line vs two lines: p <.0001, One line vs three or more lines: p <.0001 
First line therapy users only: Sunitinib vs pazopanib (p = 0.0293), Sunitinib vs temsirolimus (p = 
0.0002), Sunitinib vs bevacizumab (p = 0.0025), Sorafenib vs bevacizumab (p = 0.0332) 
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Table 4.5 Total healthcare costs per month among non-clear cell Renal Cell Carcinoma 
patients receiving targeted therapy. 
 
 Mean (SD) Median (IQR: Q1 - Q3) 
Number of lines NS   
• First line only (n = 42) 
• First and second line (n = 23) 
• Three or more lines (n = 14) 
23,619 (26,398) 
12,490 (5,835) 
12,180 (6,470) 
14,664 (9,612 - 26,010) 
10,403 (7,760 - 17,192) 
 11,116 (9,766 - 13,790) 
First line therapy users 
• Sunitinib (n = 20) 
• Temsirolimus (n = 11) 
 
32,045(35,942)           
18,499 (6,936) 
 
15,144 (9,893 - 40,586) 
20,169 (11,002 - 24,262)       
Most common class sequences 
• mTOR-VEGF (n = <11) 
• VEGF-mTOR (n<11) 
 
11,271 (5,862) 
14,660 (7,329)          
 
8,011 (7,119 - 17,643) 
11,608 (9,826 - 18,450)          
NS: not statistically significant  
Note: Significant differences were observed for the following the comparison 
Number of lines: One line vs two lines: p = 0.0323 
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DISCUSSION 
 This study examined the prescribing patterns of targeted therapies among older mRCC 
patients in the targeted therapy era. To our knowledge, this is the first study which used SEER-
Medicare data to describe the full spectrum of targeted therapies given over the lifetime of older 
mRCC patients. The study assessed the number of lines of targeted therapies, most common first 
and second lines and most common sequences prescribed to clear cell and non-clear cell mRCC 
patients. In addition, overall survival and total healthcare costs per month from Medicare’s 
perspective were described.  
The patterns of prescribing for first line treatments, for the most part, were consistent with 
the NCCN guidelines. Prescribing patterns in terms of the choice of first and second line therapy 
were similar to patterns observed in previous studies.13-15, 17 Some patients in our study received 
bevacizumab and sorafenib which have category 2-A recommendations. Among patients who 
received a second line therapy, temsirolimus, which has a category 2B recommendation, was given 
to 84 (24%) patients. This may be considered a deviation from the NCCN guidelines. A similar 
finding was also reported by Miller et al.15 In addition, sorafenib, which has a category-2A 
recommendation was less frequently used than temsirolimus. Axitinib, approved in 2012, which 
has a category-1 recommendation as a second line therapy was not frequently observed in this 
study, probably because the follow-up period ended on December 2014. Additional analysis 
among mRCC patients who were diagnosed after 2012 suggested that axitinib use increased in 
2013 and 2014.  
OS increased with the increase in the number of targeted therapies used among mRCC 
patients. The descriptive analysis suggested that pazopanib had higher OS than other targeted 
therapies. Pal et al. also assessed SEER-Medicare data and reported that pazopanib had higher OS 
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than sunitinib.18 However, Rasca et al. found no difference in OS or risk of death between 
pazopanib and sunitinib.19 Our results are primarily descriptive and did not control for prognostic 
risk, performance status or sociodemographic factors.  
Patients who received multiple lines of therapies had higher OS but OS did not differ across 
sequences. Among patients who received two lines, OS was similar between VEGF-mTOR and 
VEGF-VEGF classes. Similarly, among patients who received three lines, VEGF-mTOR-VEGF 
and VEGF-VEGF-mTOR sequence resulted in a similar OS. Our findings are consistent with 
previous studies, which did not find a significant difference in the progression free survival or OS 
between targeted therapy sequences.13, 17, 22  
The median monthly total healthcare cost was significantly higher for patients who 
received only one line of targeted therapy. This could be because patients who received only one 
line had more severe or advanced disease or had poorer prognoses, as indicated by their lower OS. 
In contrast, patients who received multiple lines could have had better prognoses and performance 
status, as suggested by their longer OS. Among patients who used a single line of therapy, median 
cost was highest for sunitinib and lowest for bevacizumab. Vogelzang et al. in a recently published 
study using Medicare data found that the THC among sunitinib users were higher than pazopanib 
users.23 However, McLean et al did not find any significant difference between sunitinib and 
pazopanib users.24 Our findings related to sunitinib and sorafenib users were consistent with Kim 
et al. who did not find a significant difference between sunitinib and sorafenib users.25 We also 
did not find any significant differences across targeted therapy sequences. However, it is important 
to note that our cost analyses were descriptive in nature and we did not control for prognosis, 
performance status or sociodemographic factors. Also, sample sizes for some drug sequences were 
low (n <20).   
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 This study had several limitations. First, SEER data does not measure cancer recurrence 
and progression. Targeted therapies were mainly approved for metastatic RCC, therefore we 
assumed that patients who were initially diagnosed at stages-I- III and had a prescription record 
for targeted therapy had recurrent metastatic disease. Second, the study could not control for 
baseline prognostic risk measured by Heng’s criteria26 or performance status measured by Eastern 
Cooperative Oncology Group (ECOG) scale27.  This could affect OS and THC. Similarly, the study 
did not measure physician and patient preferences, which are important determinants of treatment 
selection. Third, this study was conducted among Medicare patients aged ≥ 65 years at the time of 
diagnosis and living in SEER areas. Therefore, findings from this study may not be generalizable 
to younger mRCC patients or patients living outside of SEER areas. Fourth due to a two year lag 
in the availability of the SEER-Medicare data, we could not measure the use of cabozantinib and 
nivolumab, which were approved in 2016. Future studies may assess prescribing patterns of 
immunotherapies among older adults with mRCC and use data from sources that allow 
measurement of risk of prognosis and performance status at the baseline.  
Conclusions 
 Among mRCC patients who received targeted therapies, fifty percent received two or more 
lines of targeted therapies. Prescribing patterns of targeted therapies were generally consistent with 
NCCN recommendations. OS was significantly higher and THC was significantly lower for 
patients who received multiple lines of therapies compared to patients who received a single line. 
However, OS and total healthcare costs did not differ significantly by the type of targeted therapy 
sequence prescribed. 
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Chapter 5: Discussion 
Summary of findings 
This dissertation focused on three specific issues related to healthcare cost, overall survival 
and treatment modalities among older mRCC patients. The first study examined the direct 
healthcare cost and the total economic burden of RCC on Medicare. It also examined cost drivers 
of total healthcare costs by stage at which RCC was diagnosed. The second study specifically 
included RCC patients newly diagnosed at stage-IV (metastatic) and examined the prevalence of 
cytoreductive nephrectomy (CN) and targeted therapy use and comparative effectiveness of the 
combined use of CN and targeted therapy versus targeted therapy alone strategy. The overall 
survival (OS) and total healthcare cost (THC) were the main outcomes. The third study specifically 
described the prescribing patterns and sequencing of targeted therapies among mRCC patients and 
described the OS and THC among the most common patterns.  
Based on our analysis, the economic burden of RCC on Medicare was found to be between 
US $1.5 to 2.2 billion, the average THC associated with RCC was $7,419. Based on phase-based 
cost approach we found that for patients diagnosed at earlier stages, initial and late phase costs 
could be substantially higher than the continuing phase of care. For stage-IV patients though, THC 
was higher for all the phases of care due to shorter OS among these patients. This is the first study 
in the targeted therapy era, which assessed the healthcare costs by stage at which the RCC was 
diagnosed. Our findings suggested that the average THC and the economic burden varied 
substantially by the stage at which RCC was diagnosed. Despite of lower prevalence, patients 
diagnosed at stage-IV accounted for 50% of total economic burden. Patients diagnosed at stage-I 
accounted for the second largest component of the total economic burden. The average THC 
associated with stage-IV was 9 times higher than patients diagnosed at stage-I. Study findings 
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suggested that hospital costs was the primary drivers of THC for stages I-III whereas prescription 
drug cost was the primary drivers of THC among stage-IV patients. According to NCI, a 5-year 
survival rate for patients diagnosed at stage-IV is only 12%. Although targeted therapies have 
marginally improved OS among stage-IV patients, the unmet needs could be much higher among 
stage-IV patients compared to patients diagnosed at earlier stages as the OS is lowest but the 
average THC is the highest in this patient group.  
 Among newly diagnosed mRCC (stage-IV) patients, 29% received targeted therapy alone, 
9% received CN alone, and 16% received both CN and targeted therapy. About 47% did not 
receive either targeted therapy or CN, which are considered as primary treatments for mRCC. 
Prevalence of patients who received targeted therapy or CN in our study was much lower than 
previously published studies on commercially insured patients. In addition to factors such as older 
age, NCI comorbidity index score, and presence of liver/ brain metastasis, we found that living in 
the south and north central region, and rural areas was associated with lower odds for receiving 
CN. Results from survival analysis suggested that combined use of CN and targeted therapy played 
an important role in improving the OS among mRCC patients. Patients who received CN + targeted 
therapy had a lower risk of death and a higher median OS compared to patients that received 
targeted therapy alone. These findings, when taken in the context of previously published studies, 
suggest that among clinically appropriate mRCC patients CN plays an important role in extending 
overall survival. Further, lifetime cost associated with the use of CN+ targeted therapy was similar 
to targeted therapy alone group, which suggested that use of CN prior to targeted therapy use may 
not increase the monthly THC on Medicare. 
 Prescribing patterns of targeted therapy among mRCC patients, for the most part, were 
consistent with the NCCN guidelines. Findings were also consistent with previous studies in terms 
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of drug-level and class level sequencing. About 25% of mRCC patients received temsirolimus as 
a second line therapy which can be considered as a deviation from the NCCN guidelines. About 
50% of mRCC patients who received targeted therapy, received multiple lines of therapies. This 
number may increase in the future with the approval of several targeted / immunotherapies. Results 
from the survival analysis suggested that the median OS increased with the addition of an extra 
line of treatment. Study findings also suggested that among patients who received two or more 
lines of therapies, the OS and median monthly THC was similar across targeted therapy sequences. 
However, our findings related to treatment sequencing and OS or THC were descriptive and did 
not control for baseline prognosis or performance status.  
Implications 
 Several targeted therapies and immunotherapies are being studied in clinical trials for 
mRCC as well as in the adjuvant setting for patients with recurrent disease. Findings from the 
economic burden study can be used as a baseline to assess the value of emerging therapies and to 
develop key value messages for payers. Interventions that prevent or detect RCC at earlier stages 
or manage RCC with fewer complications have the potential to generate cost savings. 
Understanding of cost drivers by stage at diagnosis would help Medicare in the allocation of 
resources and annual budget planning. Findings related to the association between the combined 
use of CN + targeted therapy and OS provided an additional evidence for the potential benefits of 
CN in the targeted therapy era. Assessment of predictors for CN or targeted therapy use would 
help to identify patients that are good candidates for RCTs and to explore reasons underlying 
disparities observed in our study. Findings on prescribing patterns of targeted therapies would be 
useful to understand the extent to which targeted therapies were prescribed as per the NCCN 
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guidelines. Further, our findings provided real-world evidence on the OS and THC for targeted 
therapy sequences among older adults. 
Future research 
 This study assessed the economic burden of RCC using the prevalence-based design.  
Future research can be conducted using the incidence-based design to examine healthcare costs 
that occur during the lifetime of patients from diagnosis until death. Incidence-based cost studies 
may help to better understand healthcare cost during the initial, continuing and terminal phase of 
care. Future studies may also assess financial burden to patients and indirect costs to assess the 
societal impact of RCC. Our study could not examine the health-related quality of life (HRQoL) 
of mRCC patients who received targeted therapy and/or CN. Assessment of HRQoL in addition to 
the OS and healthcare cost would help in the complete assessment of the comparative effectiveness 
of CN and targeted therapy. Further, it would be interesting to understand the effects of timing and 
sequencing of CN and targeted therapy on the overall survival and HRQoL. Also, individually 
targeted therapies can be compared in the adjuvant setting (after CN) for their outcomes. Several 
studies including ours have assessed the combined use of CN and targeted therapy to targeted 
therapy alone. Sunitinib was the commonly assessed targeted therapy in these studies. Other 
targeted therapies and immunotherapies can be compared in the adjuvant setting for their effects 
on OS, HRQoL, and THC. 
From 2016, several immunotherapies such as nivolumab have been approved to treat 
mRCC. Combinations of immunotherapies and/or targeted therapies are also being assessed in the 
RCTs. Future research may compare new therapies and their combinations among older adults for 
their OS, HRQoL, persistence and total healthcare costs. These outcomes can be studied using the 
electronic health records in addition to registry and claims data to get the information on laboratory 
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values that are used in the Heng’s or MSKCC criteria. This would allow researchers to classify 
mRCC patients into risk groups based on their baseline prognosis and to study outcomes stratified 
by the baseline risk of prognosis. The landscape of systemic therapies has changed even further 
after 2016. As a result, selecting a systemic therapy for the first and subsequent lines has become 
more complicated. Future studies may assess prescribing patterns of immunotherapies, patient and 
physician-level factors associated with treatment choices and the effects of prescribing patterns on 
the health outcomes.  
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